HEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETS

H3 IN THE BATTLE AGAINST OLD AGE

by Henry Marx

Related Book: GH3 - Will it keep you young longer?
Related Information:
GH3 - Frequently asked questions...

How Vitacel GH3-7-8-9 works!

CONTENTS

You can click directly on the Chapter of interest below...
Preface
Chapter 1 – We face the problem
Chapter 2 – What is old age
Chapter 3 – Why do we age
Chapter 4 – Parhon – a pioneer
Chapter 5 – The Semantics of rejuvenation
Chapter 6 – A new use for an old drug?
Chapter 7 – Dr. Aslan’s claims for H3 therapy
Chapter 8 – “H3” = novocaine = procaine
Chapter 9 – Why a “rediscovery”?
Chapter 10 – Some confirming reports
Chapter 11 – Soviet research with procaine
Chapter 12 – News reaches the West
Chapter 13 – The Parhon Institute of Geriatrica
Chapter 14 – The Procaine therapy at the Institute
Chapter 15 – From Gerovital to KH3 to GH3
Chapter 16 – H3 in the United States
Chapter 17 – A rehabilitator for the aged
Chapter 18 - Diseases of the nervous system
Chapter 19 - Diseases of the muscles and joints
Chapter 20 - Diseases of skin, and allergies
Chapter 21 - Cardiovascular diseases
Chapter 22 - Gastrointestinal diseases
Chapter 23 - Effects of endocrine glands
Chapter 24 – Why procaine was “forgotten”
Chapter 24 – H3 a name for a riddle
Chapter 26 – DMAE – a related mystery
Chapter 27 – Can procaine postpone old age?
Chapter 28 – Why all the excitement about procaine?
Chapter 29 – What does H3 mean to you?

DISCLAIMER

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease.

The information on GH3 provided on this site is for educational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Nor is any of the information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.


BACK TO TOP

Preface

Eighteen years have passed since the first edition of this book was published and while much has happened during that time in the field of old age care, much has also remained the same. While the number of our elderly-those past their 65th birthday-is constantly rising, and with it also the life expectancy of this group, we still keep them on the fringes of our society.

Medicare has been introduced in the sixties-and with the improvement it has brought in the lot of the elderly, it has also led to the nursing home scandals we were satisfied in treating cosmetically without changing the system which bred them. Blue Cross/ Blue Shield insurance has priced itself almost out of reach of most retired persons who still suffer from the growth of hospital costs. Social insurance still discriminates against people working beyond their 65th year by withholding the full amount due them until they reach 72.

With the retirement age now legally raised from 65 to 70 years, it becomes apparent that we must do everything in our power to keep the elderly healthy longer. The drag to the taxpayer for not doing so is considerable: old people, who make up ten per cent of the US population, account for 29 per cent of all medical bills, much of it coming from the public Treasury (which in a recent 18 months-period, from January 1976 to July 1977, paid some 140 million bills amounting to $7.5 billion).

As long as the medical establishment and our medical policy generally remain sickness- instead of health-oriented, as long as almost all money goes into the search for elusive cures for often fatal diseases and almost none into ways to prevent them-little will be done to cut down on the ever increasing health bill. Merely to exist, as is the fate of so many oldsters, is not to live. Now that medical science has been able to extend man's life span, it must also arrest the dissolution of body and spirit that often occurs in the final years of life. Until it succeeds in making these years worth living, it will have achieved only a Pyschic victory.

I believe now, as I did eighteen years ago, that with GH3 procaine - thanks to oral therapy more easily administered now than in 1960-we possess a tool to make life for our senior citizens a real "third age" of vitality, usefulness and independence. Little did I anticipate then that in spite of the many reports confirming Professor Ana Aslan's work, our medical bureaucracy would still maintain its negative attitude towards this promising GH3 therapy in 1978, setting up one roadblock after another to prevent GH3 from bringing possible relief to millions of people.

Unfortunately, much of what has been written in newspapers and magazines or that has been broadcast on radio and TV about procaine were either ignorant denunciations, great distortions, half-truths, wishful interpretations or irresponsible exaggerations. My aim in presenting this book-then and now-is to tell the true story of GH3, one of the most exciting medical developments of our time. In close to eighty countries of the world, GH3procaine therapy has become a way of life for older people. On the basis of this book the American public should be able to judge how much hope and how much hokum lie behind the headlines.

Before writing the first edition I twice visited the Institute of Geriatrics in Bucharest and enjoyed the fullest cooperation of Prof. Aslan and her associates. I have also consulted non-Romanian physicians with clinical GH3 procaine therapy experience, and have read scores of scientific papers published in the interim.

As I said in 1960: I hope I have succeeded in my attempt to present the GH3 material so gathered without prejudice and without emotion.

January 1978

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3


BACK TO TOP

Chapter 1

We face the problem

In the early years when men still ate lizard's tongue and mandrake root as cures, only the strong-the young-were equipped to survive the myriad dangers and diseases rampant upon the earth. (Indeed, in many cases only the young were sufficiently well equipped to survive the cure I) The aged were too slow to flee from fire or flood. They could not slay a wild boar, nor even outlive a witch's curse. They were the easiest of prey in a world in which even the fit could not survive all the machinations of plague and famine. The human race was young. But already the old were outdated.

As time went by, the struggle for mere survival was easier. Man had learned to couple his energy with the resources about him. Now he had other tools with which to fight. He could live out his natural life, and dared even to dream of extending his life span.

(It is interesting to note that almost all the tales which mirror man's dream to live out his natural life with vigor and independence are permeated with an aura of the supernatural or anatural. Did not Faust have to sell his soul to the Devil? What of Daniel Webster's classic debate with Scratch? And the narcissistic Dorian Gray?)

Despite the connotation of evil surrounding such a course, man rejected the image of an unproductive future. Ponce de Leon searched for the Fountain of Youth in an era in which man still chased myth. (Interestingly enough, some three hundred years later the land on which he sought eternal youth has become a "paradise" for the aged.) The Bible relates King David's request for young girls to be placed in bed with him in order to effect the monarch's rejuvenation. While the scriptures do not elaborate upon the dynamics of such a "cure," centuries later man still believed in the rejuvenating power of inhaling the breath of the young: the famous Dutch physician Hermann Boerhaave recommended such a therapy as late as the 18th century. However, rejuvenistic literature was in its heyday during the middle ages, when superstition was riding high and magicians, alchemists and charlatans had the field to themselves.

Roger Bacon disclaimed any belief in magic. However, his writings indicate that as far as the possibilities for rejuvenation were concerned, he was by no means more enlightened than were his colleagues of the 13th century. Paracelsus was the most famous physician during the 15th century, and while lately some of his ideas have been resurrected, his arcanum for immortality has long been forgotten (perhaps because he died at the age of only 48).

Nothing approaching a scientific attempt at rejuvenation took place until the end of the 19th century. At about the same time that Pasteur experimented with anthrax and William Morton introduced ether anesthesia, a French scientist, Charles Edouard BrownSequard, astonished his associates at the Societe de Biologie by appearing before them, after several months of seclusion, looking at least twenty years younger than when last they had seen him. BrownSequard was a man of 72 who haad lost his zest for life-only the scientist in him could not be subdued. He proudly explained to his audience that through the injection of animal testes he had "rejuvenated" himself: his irritability and impotence were gone, his gastrointestinal and urinary problems had diminished. At the same time, his muscular power had increased, which he demonstrated with the aid of an ergograph (a mechanism designed to show graphically the work and fatigue of muscles).

Brown-Sequard, until then a highly respected scientist, soon found himself condemned by many of his peers. The results of his self-experiment were ascribed to his "senile-erotic imagination." Nevertheless, although he had by no means "rejuvenated" himself, he had demonstrated the importance of internal secretions to the vigor and strength of the human body. Unfortunately, his method did not combat old age, but succeeded merely in activating the organism.

Only 17 years after Brown-Sequard's death at the age of 77, and in the shadow of Ehrlich's discovery of Salvarsan, the Viennese physician Eugen Steinach advanced another theory: he advocated tying off the spermatic cords, thus preventing the production of wasted sperm, and increasing the internal secretion which is passed into the bloodstream. He thought aging to be connected with the involution of the interstitial cells of Leydig, cells in the testes which to this day have not been isolated and whose function has never completely been explained. Steinach named the interstitial cells "puberty glands," and proceeded to effect a "surgical reactivation" of the male by so-called vasoligation. The operation, performed under local anesthesia, was a difficult one which provided only temporary benefits. Today, Steinach's operational technique is used only occasionally, in cases of urinary complications.

While the Scottish bacteriologist Alexander Fleming was growing mold cultures in a search that culminated in penicillin, Dr. Serge Voronoff, soon after World War I, stirred up a great deal of curiosity by grafting monkey sex glands on humans. Again, the effects were not lasting. V oronoff himself claimed only that he could prolong the vigor and joy of life for five to six years by this method, after which one more grafting operation (not entirely without danger) was feasible. However, should the individual survive twelve years, he was doomed to hopeless senescence, which perhaps made things worse than they were before.

Voronoff was, in turn, followed by the Russian physician and biochemist Alek.sandr A. Bogomolets, who developed ACS (antireticular cytotoxic serum), based on his premise that stimulation of the physiological system of the connective tissue was of great importance in preventing morbid aging. His serum was supposed to retard the gradual exhaustion of the body, thereby delaying the onset of senility.

This theory enjoyed a brief vogue, but when Bogomolets died (at the age of only 65), most of the ardent supporters of his theory turned their attention to the newly discovered sulfa drugs.

Was it a quest for personal immortality that stimulated Brown-Sequard or Steinach? Voronoff or Bogomolets? Who can tell? We do know that the time was ripe for the discovery they were seeking. Medical science had already made great advances. Men over forty were no longer considered old, and those over sixty no longer so rare as to be venerated for their age alone. Painful, helpless old age was soon to become a major medical and social problem, but these first scientific attempts to preserve true life in the aged unfortunately held the attention only of sensationalists and fanatics. The attention of medical scientists was still directed to the most pressing medical problem-the control of infectious diseases. The goal of less. disease had to be reached before the problem of healthy longevity could command widespread research attention. Furthermore, the substrate of biological knowledge essential for true progress in this field was not available at that time.

Unsophisticated as were these pioneer attempts by scientists to preserve vigor throughout old age, they nevertheless presaged one of the most ironic dilemmas of modern times. We have learned how to keep ourselves alive to a ripe old age, but we have not learned how to make this old age worth the living.

Now that the scourges of bubonic plague, smallpox, malaria, typhoid, yellow fever, and polio have been checked, and we have learned to use vitamins and antibiotics, blood banks, and new surgical techniques, we are confronted with the success of our toil. The numher of people over 65 doubled in the United States between 1900 and 1950, and since then has continued to increase.
Today, more than 23 million people, or a little over 10 per cent (compared with only 4.1 per cent at the turn of the century) are over 65. Within the next fIfty years their number in a fairly stable population will have increased to 45 million. This means that in the year 2030 the number of women over 65 will equal the number of girls under 15. To put it in another way, the median age of Americans will climb from 28.9 at present to 37.3 fifty years hence (at the beginning of the nineteenth century the median age was barely 16).
Thus achieving longer life for so many, we cannot afford to stand idly by while they (and eventually ourselves) become prey to the multitudinous complications of old age.

The "graying of America" adds to our responsibility to provide for retired people in such a way that the "golden age" does not become a hollow phrase. A few years ago, Lincoln Day of the United Nations statistical office reported to the Commission on Population Growth and the American Future: "To worry about the supposed behavioral consequences of an aging, or more aged, population, is to divert attention from the real issue: how to incorporate a higher proportion of old people into society in a socially and emotionally meaningful way."

Once the aged were victims of man's weakness and ignorance. Today they are the victims of his knowledge. They are alive-but they cannot flee from their loss of independence, they cannot fight the diseases that plague them, they cannot outlive the curse of senility. The old do not die as easily today; they linger, they whimper. The strong must still carry the weak-and fewer must carry them for a longer time.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 2

What is old age?

Different manifestations of old age have been catalogued for many years, but scientific attention was not directed to them until a half-century ago. A New York physician, Ignatz Leo Nascher, coined the word "geriatrics" (from the Greek "geron," meaning old man) and applied it to that special branch of medicine which deals with the typical diseases of the advanced years. The word" gerontology," meaning" study of old man," was derived, naturally, from this root. Thus, while the former - geriatrics - denotes the practice" of medical means to alleviate the results of aging, the latter term (gerontology) categorizes the theory of aging.

The most perplexing questions facing medical science today concern the causes of old age and the precise measurement of the process of aging in the human body. We are all familiar with the manifestations of age, but we are not sure whether its signs and symptoms are inevitable, as believed until quite recently, or whether they can perhaps be postponed, or even completely prevented. The growing number of biologists and physicians who advocate the latter believe that the signs of old age are merely indications of a sickness which should yield if properly treated. They point out that chronological and biological age do not necessarily coincide-that some people, in appearance, attitude and behavior, seem younger than they really are, while others appear older. Why this should be so, has never been answered satisfactorily.

The aging process actually begins at birth, but at the onset these changes lead to growth and maturity. Once the latter stage has been reached, a slow decline sets in-affecting different parts of the body at different times, sparing some organs until a fairly advanced age. Thus, it has be-en found that hearing is best at the age of 10, vision at 20, muscular strength and coordination at 25, and reproductive functions at 30. These few examples suffice to show that aging is a slow process, and that it does not affect the entire organism at any single specific time. We speak of "normal aging" and "accelerated aging;" but although our yardstick for the former is still rather vague, there is general agreement that the latter is due to morbid changes in the body.

While the true causes for the decline of vigor in man are not known, we do know that the symptoms which accompany his slow but steady decline usually gain momentum during the fifth decade of his life. The first evident changes are connected with his appearance: hair becomes sparse and grey, shoulders develop a slight stoop, the skin shows wrinkles and the gait loses its earlier buoyancy. Man begins to "look old," although at this stage of the aging process he may not feel old. In fact, because he maintains his activities at the high level of youth, without much change in his way of life, he may well be laying the groundwork for future illness. (An investigation into the dynamics of "middle-age medicine" is another program still to be developed.)

Other symptoms enter the picture: the metabolism is less active, recuperative powers slow down, the energy used up by the body is replaced at a much slower rate, thereby rendering the tissues of the individual organs more flaccid. The skin becomes thinner and, due to a reduction in the secretion of some of its glands, drier. As the years progress, muscles fail to maintain the body in its former erectness, motions lose some of their power and sureness. The thorax is no longer expanded as before, partly due to increased muscle weakness, partly to an ossification of the costal cartilages. Thus, the lungs do not receive as much oxygen, the walls of their air cells become thinner, breathing is less thorough, and the respiratory metabolism slows down.

Bones become more brittle, they decrease in volume and weight, almost all cartilages lose their elasticity and, in certain spots, calcify. A great many of the capillaries in which blood is transported to distant parts of the body become clogged, preventing an even blood supply (the reason for circulatory troubles in the extremities, as well as opacity of the cornea, which leads to cataracts). The digestion, too, becomes impaired; teeth are no longer as efficient as they formerly were; liver, gall bladder, spleen and pancreas are weakened; the absorption of essential vitamins and minerals from the intestines is reduced. The slowing down of the metabolism as a whole also affects the mental acuity and an increase in forgetfulness; the severest, psychosis and regression to infantile behavior. Between these two extremes we find apathy, confusion, hostility, restlessness, sloppiness, asocial attitudes, sexual aberration, and persecution feelings.

Why some people become senile and others do not is still unknown. Social and psychological stresses play a part, but of primary importance are the changes in the body. Hormonal disturbances, a malfunctioning enzyme system, and lowered activity of the brain cells (stemming from a reduction of the cerebral blood flow) seem to be the main causes of man's mental deterioration.

Dr. William Malamud of Boston University has stated that the incidence of mental disorders in old age has been rapidly increasing for the last three decades and, particularly since the end of World War II, "has skyrocketed to a degree totally out of proportion to any of the other types of personality disturbances."

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 3

Why do we age?

The signs of old age are no more profuse than the theories attempting to explain its cause or causes. This is hardly surprising, for no common denominator has been found as yet. There is not even agreement as to how many years constitute man's natural life span. Each plant or animal has a maximum life expectancy, which cannot be exceeded even if the organism remains healthy. The fact that almost no one dies of old age per se would indicate that most of us never reach our full potential. But what is our potential life span? Biologists measure it against the time maturity is achieved or bones stop growing in length, and their resulting figures are that man should live for 120 to 150 years! But no generally accepted criteria exist: man's natural life span is still a matter of speculation.

Aging, according to one school, is due to an exhaustion of life energy; another holds that it is due to a slowing down of the metabolism (although it may be questioned whether this is not the consequence rather than the cause). A third group maintains that the flooding of the organism with toxins is responsible for aging; Metchnikoff, one of the first scientists to occupy himself with this problem, was convinced that autointoxication caused old age, and that death followed the accumulation of fatal toxins in the large intestine. A more mechanical hypothesis, which was developed many years before the first atomic explosion, deals with the possible effects of cosmic radiation on the life span. The involution of individual organs (i.e., sex glands, ovaries, thyroid or other endocrine glands) was blamed for aging by a school which believed that renewed vigor could be conferred on old people through a genuine reactivation of these glands. Also, the degeneration of the nerve cells, in particular a creeping paralysis of the central nervous system is considered by some as the primary cause of aging.

One of the more widely accepted theories of aging is that of Dr. Hans Selye of Montreal. The originator of the concept of stress diseases, he defines stress as the "rate of wear and tear in the body." This wear and tear is a continuous process and has a cumulative effect. According to Selye, each human being (or animal, for that matter) has only a certain amount of "adaptation energy" with which to replenish his vital reserves. Theoretically, this reserve shrinks a little after each stress, and the deficit in adaptation energy, occurring from day to day, "adds up to what we call aging."

Among the first signs that the body is failing to adapt itself to stressful situations are the many allergic diseases, such as hay fever, certain rashes, and asthma. And the diseases of old. age are for the most part caused not by invasion of the body by germs or viruses, but by failure of one or another part of the body to adapt to the stress of life.

To quote Dr. Selye: "Among all my autopsies (and I have performed quite a few) I have never seen a man who died of old age. In fact, I do not think anyone has ever died of old age yet. To permit this would be the ideal accomplishment of medical research (if we disregard the unlikely event of someone discovering how to regenerate adaptation energy). To die of old age would mean that all the organs of the body would be worn out proportionately, merely by having been used too long. This is never the case. We invariably die because one vital part has worn out too early in proportion to the rest of the body. Life, the biologic chain that holds our parts together, is only as strong as its weakest vital link. When this breaks, no matter which vital link it may be-our parts can no longer be held together as a single living being."*

Since living cells in a water solution can be kept healthy for an infinite period of time by cleaning them and returning them to a fresh solution, Selye advanced the idea that the weaknesses of old age may be due partly to an accumulation of waste products which interfere with the nourishment of the cells.

If this is the mechanism of aging, Dr. Selye points out, there should be at least two ways of avoiding it. The rate of waste production might be slowed down, or the system might be helped to destroy its waste and get rid of it. Research on this and other approaches to the causes of aging has been conducted by Dr. Selye and his staff at the Institute of Experimental Medicine" and Surgery in Montreal, which he founded in 1949 and has directed ever since.

The Stress of Life New York McGraw-RiU.

Dr. Selye believes that medicine has now assembled a fund of knowledge that will serve as a point of departure for studying the causes of old age. Several times he has restated his belief that aging may be regarded as a disease and. . . "like any other disease, it is probably preventable or curable. . . The truth is that death by disease is largely avoidable."

Another explanation of aging simply has to do with the fact that the reproductive capacity of the cells, the basic building blocks of the body, begins to deteriorate. Cells, as we have learned, have different life spans: an epithelial cell in the intestines, forming with other cells the tissue that lines our alimentary canal, lives for only 36 hours. Red blood cells reach an age of 120 days, white blood cells of only 13, but nerve cells last forever.

As the human body grows older, the cells are no longer able to reproduce and to grow as quickly as in younger people. That's for instance why in advanced years your body no longer can heal a wound as fast as when you were 30 or 40 years younger. Also that part of the cells which manufacture proteins no longer functions with the same efficiency as in the young person. Dr. Nathan Shock, once head of the Gerontology Branch of the National Institutes of Health, developed a theory that the failure of individual cells to replace and renew themselves throughout the organism causes its slowing down, i.e. aging of body functions. If there . are too many dying cells in the body and if too many of the irreplaceable cells cease to function, the entire organism will collapse and eventually die.

Vitacel GH9 - Vitacel G-H8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3


BACK TO TOP

Chapter 4

The Parhon Institute of Geriatrics — A pioneer of GH3

One year after Nascher had coined the word "geriatrics," and while Hans Selye was still a schoolboy, a young Rumanian physician named Constantin I. Parhon took the position that old age is a treatable disease. The first Rumanian medical figure to achieve international renown, Parhon began his career as a neurologist but soon became attracted to the functions of the endocrine glands. On the basis of experimental and clinical research he began administering an extract of the pineal gland (a small gland attached to the posterior of the brain) to old people. While his method was much simpler than that of Steinach, his successes were by no means more definitive. However, continuing his endocrinological studies, he found that animals would develop signs of old age if certain glands or tissues-such as the thyroid, the spleen or the mammary glands-were removed surgically. His treatise on the importance of the endocrine glands, published almost 70 years ago, is considered the first large scale endocrinological work in medical literature.

For 40 years Parhon continued his investigations into the causes of aging. His aim was to determine the true biological age of human beings. During 22 of those years, Parhon was a Professor of neurology, and it was not until 1934 that a chair of endocrinology was created for him at the University of Bucharest. Six years later the Rumanian Fascist government fired him, but he returned to his former position in 1945. I was soon thereafter that he founded the Institute of Endocrinology.

Professor Parhon's views can best be summarized in his own words from one of his more than 1,200 publications:
"From a theoretical point of view, I am of the opinion that aging begins simultaneously with growth and development, and that the mechanism of aging can be understood only in terms of research concerned with the changes which the entire organism undergoes throughout its lifetime. The phenomena that determine and accompany the aging process are so numerous and involved and their mode of origin so deserving of study that they cannot but fascinate all biologists. . .

"I am of the view that the process of aging occurs only to the extent that the conditions giving rise to it have occurred. If one were able to interfere with the mechanisms of aging, the direction of this process would be subject to change. In this way it is conceivable that the aging organism, whether the aging is due to premature, pathological, or so-called normal factors, could be returned to an earlier biological state. My experiences . . . have shown that the rhythm of life can be either speeded up or slowed down at all stages. . . . Biological and chronological age are not necessarily identical. Differences in aging rates can also be observed in clinical situations, e.g., endocrine conditions, and I believe that the rate of aging, 'the film of life' as it were, can be controlled in either of two directions, Le., toward faster aging or, to some extent, toward rejuvenation.

"If one were to view the aging process as irreversible, steps to control it would involve merely sanitation and the usual treatment. But if the aging process is regarded from a functional viewpoint, as a deviation from the normal functional optimum of the individual, Le., as an abnormal phenomenon, then treatment no longer seems impossible. In our view the aging process is a pathological condition, or, to state it better, a more or less extensive dystrophy. . . which develops slowly as the organism grows and differentiates. It is our obligation to treat these disturbances of function, and to prevent them whenever possible."

Parhon's interest in the problems of aging (in 1926 he coined the word "ilikibiology" from the Greek "iliki" meaning old age, but this never gained wide acceptance) led, in 1951, to the founding of the Institute of Geriatrics in Bucharest. Parhon, who had been elected the first President of the Rumanian Republic after the fall of the monarchy in 1948, returned to his scientific work when the Communists took over the country in 1950. He then had at his disposal facilities which made it possible for him to pursue vigorously his important work. The nucleus of the Institute was an existing old age home with almost two hundred inmates. These were the people through whom Parhon wanted to prove definitely that old age could be treated. All of the inmates suffered from serious degenerative diseases; he proceeded to give them either tissue extracts (of the spleen or placenta), gland extracts (adrenal and pineal glands, thyroid), vitamins (Vitamin E, liquid beer yeast), or baths of bicarbonate of soda (a treatment developed by the Russian physiologist Olga Lepechinskaya, which had received wide publicity in the Soviet Union in the post-war years). All of these treatments had been tried previously at other institutions, and the results in Bucharest were about the same: a few of the old people seemed to benefit, but no really important changes took place.

In 1949, a woman doctor who for more than 20 years had been a specialist in cardiovascular diseases joined the staff of Dr. Parhon's Institute of Endrocrinology. Prof. Ana Aslan had long been interested in the pharmacodynamical properties of novocain* and jts action in the human body, and she continued her experimentation under Dr. Parhon's direction-and under the encouragement of his conviction that old age and its manifestations are treatable and preventable.
It would seem that Dr. Parhon was impressed with the capabilities of his new staff member, and with the direction and progress of her research, for in 1952 Parhon turned over the directorship of his Institute to Prof. Ana Aslan.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 5

The semantics of rejuvenation

The story of Prof. Ana Aslan and the therapy for the diseases, discomforts, and agonies of old age developed by her and her co-workers at the newly founded Parhon Institute of Geriatrics is an exciting one, it has also been frequently misrepresented.

When we are children, we can hardly wait to be grown up. At some point, we reach that very satisfying period of life when the privileges and pleasures of maturity are combined with an eager zest for life and with the vigor of youth. This delightful stage-usually the late teens to the late twenties or early thirtiesgoes by most of us unnoticed and unappreciated (how often do the middle aged and older quote the phrase "youth is wasted on the young"). Then some little sign-a hair line thinner at the temple, some wrinkles around the eyes-reminds each of us that, like all living things, we too are subject to the aging process. And one day, for the first time, the thought flashes through our mind "If I were young again. . ."

This thought is father to the wish. But if we no longer believe in the curses of witches, neither can we hope for the magic wand of a fairy to touch us and restore youth and beauty. There is no way to turn the clock backward. So most of us go on about our living, the wish to be again young (or at least middle-aged) buried in our subconscious. The word rejuvenation, expressing this buried wish, is perhaps charged with more wishful thinking than any other word in our language.

For this reason it was unfortunate that Prof. Aslan originally used the words 'true rejuvenation' in describing occasional effec.ts of the therapy she had developed. For her words have been picked up by headline writers and newscasters, and shortened into such deplorable catch-phrases as "Youth shots," "Youth serum," "Long-life drug," "miracle drug," and even "Live-forever juice." .

Webster's unabridged dictionary defines rejuvenate as follows: -To render young or youthful again; to impart renewed vital ity to. (Med.) To restore to a more youthful condition; speci£ically., to restore sexual vigor, as by an operation.

Professor Aslan has used the term rejuvenate in the restricted sense of "to impart renewed vitality to . . . to restore to a more youthful condition." In this limited, more symbolic sense, rejuvenation is a phenomenon familiar to us all. Our vitality is renewed when we convalesce from a serious illness, or vacation after a long period of strain or over-work. Surely we . are restored to a more youthful condition as we recover from the shock and grief of the loss of a dear one, or have some great worry lifted from our shoulders. In fact, nature imparts renewed vitality to us and restores us to a more youthful condition each time we enjoy a good night's sleep.

Nowhere in any of her published reports or public statements have Prof. Aslan or any other serious scientists who followed in her wake ever claimed to be making old men and women young again. Any restoration of sexual vigor which has occurred in any of the treated patients has been incidental to the renewing of vitality in that particular patient.

The media, however, loved the word "rejuvenation," using it in the widest possible sense, thus perhaps unintentionally but no less severely damaging the cause of this promising drug.
Once this semantic problem is well understood, we can more easily examine the basis of the claim that the procaine treatment will «impart renewed vitality to old men and women," and "restore them to a more youthful condition.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3


BACK TO TOP

Chapter 6

A new use for an old drug

Ana Aslan was born in Bucharest in 1898. Her first ambition was to be an aviatrix, but her middle-class parents were able to dissuade her. They were not so successful with Ana's second, but perhaps more mature, choice of a life work. When they refused to give her permission to enroll as a medical student, Ana Aslan went on a hunger strike. Four days later her family gave up. In 1924, Ana Aslan received her doctor's degree from the University of Bucharest.

For sixteen years, she was an assistant at the Second Clinic in Bucharest under Prof. D. Danielopolou, whom she reveres as her teacher. She held positions in other hospitals as well, and, except for three years during the post-war period when she was director of the Clinic in Timisoara, has always remained in the Rumanian capital.

Immediately after World War II, Prof. AsIan learned of a therapy which had been pioneered. by three French physicians, Dos Ghali, Bourdin and Guiot. The doctors had injected novo cain into the cubital vein twice within two hours in an attempt to effect relief in patients suffering from asthmatic attacks, and their method was successful where others had failed. Prof. Aslan found that she, too, could help asthma sufferers with repeated GH3 injections.

Then, in 1948, the noted German physician Prof. Gustav Spiess died. He had been first to discover that novocain not only has value as a local anesthetic, but also has curative power. Prof. Aslan read his obituary in a Rumanian medical journal which noted his former achievements. After checking through the literature, she immediately extended her novocain treatments to include patients with arthritis and limb embolisms, using the method devised by Rene Leriche, which even ;went further than Spiess' original idea. Leriche had advocated the infiltration of 10 to 25 cc of novocain, and was able to restore the affected joint or limb to full activity, often after as few as two treatments. Prof. AsIan, encouraged by her first results with novocain, began to use it also in cases of arthritis and arthrosis with a tendency toward the fixation of a joint (ankylosis).

The efficacy of the treatment was confirmed in the very first test:

"G. J., a medical student, came to us with arthritis of the right knee, having had severe pains in his knee for three weeks. After intra-arterial injection of 0.10 g of 1 per cent novocain, he was immediately able to flex his joint up to 90 degrees."

Before proceeding on a larger scale, she thought it best to experiment with animals. Dr. Selye had already reported a method for inducing experimental arthritis in mice. When a drop of some irritant solution, such as formalin or croton oil, is injected under the skin of the sole into one of the hind paws of a rat, local experimental arthritis develops. First there is acute swelling at the site of injection, and this swelling gradually transforms itself into a chronic arthritis of the many small joints in the paw, and especially of the ankle joint. The rat becomes permanently crippled, because the joints stiffen with hard connective tissue, so that they can no longer be moved.

In the course of her experiments on mice in which arthritis had been induced by a slight modification of this method, Prof. Aslan and her coworkers at the Parhon Institute of Endocrinology (which Prof. Aslan had joined in 1949) not only found that the novocain had a therapeutic effect-they also observed that the treated animals gained weight, and developed a lustrous fur. Complete cures were achieved in 85 per cent of the affected animals, and resistance to the experimentally induced arthritis was greater in the prophylactically treated animals.

After this series of successful animal experiments, she began treating a group of selected patients between 1949 and 1951. Not all of them were helped, but improvement in many cases was gratifying to the doctors at the Parhon Institute, for they had not achieved really effective results with any other method.

While proceeding with these treatments, Prof. Aslan made a most important observation: the patients, in her own words, "showed a change in the psychological and physical conditions, an improvement in memory, a decrease in rigidity due to Parkinson's disease, and an increase in muscular power." Prof. Aslan then checked through the literature again. She could not find a single reference to any such effect of novocain. However, she had witnessed those changes with a trained, professional eye-the patients appeared younger than before, much more alert, and seemed to be enjoying life again.

Of course, it was possible that some of these changes might be due merely to the cessation of pain, and to the fact that hope had replaced the depression and resignation which had consumed the patients. There was still no proof that any physico-chemical changes were occurring in the bodies of the novocaintreated patients which would not have occurred as the result of a balanced diet, normal regime, and 'tender loving care'.

Professor Aslan then selected 25 of the patients, and for three years treated them with novocain, while all the others continued to receive only gland extracts, vitamins, etc. The apparent greater vitality and improvements in specific diseases of the novocain-treated : group, as compared to the others, were convincing to the Professor and her co-workers, although they still did not detect any significant physico-chemical changes.

In 1955 she published her findings in the Journal of the Rumanian Academy of Science (Bulletin Sintific Academia Republicii Populare Romime). This paper, entitled "La novocaine, facteur eutrophique et rejeunissant dans le traitement prophilactique et curatifde la viellesse" (Novocain-a eutrophic and rejuvenating factor in the prophylactic and therapeutic treatment of aging), contained a report of her work on the "25 cases."

As might have been expected, her Rumanian colleagues who knew of her work but had not seen its results considered it nothing short of preposterous that she make such fantastic claims. Few non-Rumanian doctors follow the proceedings of the Rumanian Academy, and thus the knowledge of this therapy was confined to its country of origin. But, fortunately, not for long.

Shortly after the Academy report was published, a German journalist traveling through Rumania paid a visit to the Institute, and included a paragraph or two on its work with old people in his articles. Those few sentences attracted the attention of Farbwerke Hoechst, a West German drug firm, which had been the sole manufacturer of novocain in Germany since its discovery. This unsuspected new use for novo cain intrigued the company, which several years before had issued a booklet detailing the therapeutic versatility of this substance. Doctor Horst Weeke, medical director of Farbwerke Hoechst, was sent to Bucharest to investigate the matter. Upon returning to Frankfurt, Dr. Weeke wrote a very positive report on Prof. AsIan's accomplishments. This report was not published, but instead was circulated among some quite important German medical men. As a result, Prf. Aslan received an invitation to attend the Karlsruhe Therapy Congress (one of the best known German medical conclaves) and to read a paper on her discovery.

September 3, 1956 was the date on which Prof. AsIan faced her first Western audience. The two dozen people listening to the obscure Rumanian doctor were skeptical and filled with incredulity at her tales of the apparent rejuvenation of old people. The applause she received was thin; indeed, the doubts which hushed the congress could be seen on every face, and some even spoke openly of a "great hoax." The meeting was concluded with the sentiments that Prof. AsIan's remarks did not belong in the program of a reputable medical congress.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3


BACK TO TOP

Chapter 7

Dr. Aslan's claims for GH3 Procaine therapy

What had Prof. AsIan actually said to engender such skepticism?

She had described her experiments and their results, in the 25 original cases, and the 45 old people who were being treated at that time as residents of the institute. She cited some specific case histories from the original group of patients, and summarized her observations of the results of GH3 therapy in both the in-patients and 2500 oldsters who were being treated on an out-patient basis, as follows:

"Our initially cautious and limited investigations, originally restricted to twenty-five cases, have been expanded appreciably in the last two years, thanks to the innocuousness of the substance involved (novocain) and to the successes gained.

"ClinicaUy we have achieved a reversal of phenomena which until now have been considered irreversible, e.g., in cerebral arteriosclerosis. Sustained improvement was achieved in cases of senile Parkinsonism, improvement in hearing, and in certain reflexes which could not be elicited prior to treatment. Also, renewed production of estrogens and of characteristics resulting from stimulating of testes and adrenal glands, retrogression of signs of senility of the skin, such as ichthyosis and senile keratosis, repigmentation of existing hair, stimulation of new hair growth, and fewer arteriosclerotic symptoms.

"Physiologically we found improvement of the central activity of the nervous system, improved cardiovascular reaction to stress on the part of old people, decreased oxygen consumption, better muscle power.

"Biochemically we found alterations in protein structure and in the ratio of albumins to globulins, increase in cholesterol (as compared to lower than normal values prior to initiation of treatment).

"Hematologically we found fewer leucocytes, higher production of granulocytes, increase in the number of monocytes and the globulin content.

"Eutrophic action was clearly visible in cases of atrophic ulcer, stomach ulcer, dermatosclerosis, psoriasis, rashes, alopecia areata and leucoderma.
"It can be stated that novocain reduces the biological age of those treated with it below the chronological age. Novocain affects directly the cerebral cortex and its dynamics, and acts on the whole nervous system, the diencephalon centers, the spinal cord, peripheral nerves, metabolic processes, and brings about trophic changes in the entire organism. It also affects the endocrine glands. Through its vitamin-like action (due to its content of para-aminobenzoic acid) it also acts favorably on the biocatalysts, and it seems to stimulate the intestinal flora to the production of biogenic agents.
"Its trophotropic action can also be observed in arteriosclerotic processes. Its effect in mobilizing the cholesterol of the blood vessel walls may be due to its hydrotropic action, characteristic of the chlorides of para-aminobenzoic acid.

"Novocain minimizes the feeling of sickness and leads to a heightened desire and capacity for physical and mental activity. By virtue of its trophic action and its role as stimulator in most vital processes, it may be considered a useful prophylactic and therapeutic substance in the fight against old age."

Why did the doctors in Karlsruhe find these words impossible to believe? First, undoubtedly, because the word "rejuvenation" brought back memories of the Brown-Sequard fiasco, and they had not listened attentively enough to realize that Prof. Aslan was by no means claiming that her therapy would make old people young again. Yet even her modest claim". . . a useful prophylactic and therapeutic substance in the fight against old age. . ." seemed too good to be true.
Her suggestion that novocain be termed "H3" may also have led some inattentive listeners to believe she claimed to have discovered a new substance. And, finally, there was still no scientifically unassailable proof that even if all Prof. AsIan reported was true, novocain deserved the credit. We will discuss in a later chapter the type of rigidly controlled experiments which will be necessary to prove finally or disprove the efficacy of novocain injections in old age.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 8

GH3 = novocain = procaine

Perhaps the closest comparison to the claims Prof. Aslan made for novocain lay in fiction: the drug «Soma" induced a sense of bliss with small doses, brought visions with larger doses, and, finally, refreshing sleep to the inhabitants of Huxley's «Brave new World." The history of novocain is almost as interesting.

Local anesthesia with cocaine was introduced by Carl Koller in 1884. Koller, a Viennese opthalmologist, had his attention directed to this drug by Sigmund Freud, then a young doctor. Cocaine had been extracted from the South American coca leaves some twenty-five years earlier, but its importance remained uninvestigated. When Koller used it, first on the eyes of frogs and then on human beings, he marked the beginning of local anesthesia. Freud, who originally had the idea, was given no credit for his foresight.

There was no question concerning the efficacy of cocaine. Once put into practice it altered many surgical procedures. But it was also clear that this was a highly toxic substance, and, furthermore, it created a feeling of euphoria which some patients valued highly. Many of them became cocaine addicts, thus inverting any benefits they might have received from its use. In 1905, Alfred Einhorn, a German chemist, produced procaine hydrochloride (the generic name for novocaif) by combining para-aminobenzoic acid and diethyl~ amino-ethanol. While there is no chemical relationship between cocaine and novocain, the latter has the same effect as the former except that it has a considerably lower toxicity and is nonhabit-forming. Many other substitutes for cocaine have been synthesized since then, but novocain has remained the most widely used.

The novocain with which most people who have had teeth drilled or extracted are familiar is the hyd-' rochloride of procaine. This hydrochloride has the chemical formula C13H2002N2HCl.

The structural formula of procaine is. . . a relatively simple compound when compared to the complex pharmaceutical substances which have been synthesized in recent years.

Novocain consists of small, colorless, tasteless crystals, easily soluble in water. It is generally well tolerated, and up to a concentration of 10 per cent, produces no noticeable irritation of the tissues. While cocaine is excreted slowly, novocain is hydrolyzed within 20 to 30 minutes and detoxicated by the blood and liver. The toxicity depends, therefore, less on the dose than on the route and speed of injection or infiltration. There is never any addiction to novocain, nor does the body develop a tolerance which would make larger doses necessary in order to bring about the desired results, as is the case with cocaine or morphine.

Novocain is hydrolyzed with the help of an enzyme, called procainesterase, which is present in some of our tissues. The products of breakdown-the same from which the novocain was made-are para-aminobenzoic acid (actually a vitamin) and diethylamino -ethanol, both considered virtually nontoxic. When, however, efforts were made to have some of the pharmacological properties of novocain explained through the use of its products of hydrolysis, researchers were time and again frustrated by the fact that the effects which they tried to produce eluded them. Continued experimentation confirmed the theory that, in dealing with novocain, the whole is more than the sum of its parts.
Prof. Aslan also attempted to produce the same effect with the vitamin component of novocain-its para-aminobenzoic acid.

This attempt was not successful, and because she did not (and still does not) know exactly what part or parts of the drug novocain caused the revitalization and reinvigoration she had observed, Prof. Aslan and her co-workers in Bucharest gave this unknown factor the name "Ha," to distinguish it from its component vitamin, which is a member of the B-complex of vitamins and is known as H1, and from folic acid, which is also a B-complex vitamin and is known as H2.

When news of Professor AsIan's therapy began to make headlines in England and the United States, newspaper reporters found it much easier to fit GH3 into a headline than either the familiar novocain, or the precise chemical name-procaine. An impression was thus unfortunately created that the Rumanian doctor had discovered some new drug, or that some mystery ingredient had been activized. Nothing could be farther from the truth. To put it most simply, GH3 = novocain (a trade name) = procaine.

Subsequently we shall refer to this drug as procaine, in accordance with the preference of American and British doctors and biochemists.
The Rumanian substance has since also become known as "GH3", "Gerovital H3," "Aslavital" and "Gero-H3-Aslan; and under one of those names is sold today in 72 countries of the world-all important ones with the exception of the United States, Canada, Sweden, Norway, and Denmark.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3


BACK TO TOP

Chapter 9

Why a rediscovery?

At first, procaine was employed exclusively as a local anesthetic, but physicians soon began to discover that GH3 also had certain therapeutic effects. Even before the advent of GH3 procaine, Carl Ludwig Schleich showed that certain rheumatic diseases and muscle pains could be controlled with the infiltration of cocaine. However, his reports were largely ignored. In 1906, Gustav Spiess pointed out that inflammations could be rapidly reduced with GH3 procaine injections.

"An inflammation will not break out if we succeed in eliminating the reflexes in (certain) nerves starting from the focus of infection, through anesthesia. An inflammation already existing is cured rapidly by anesthetizing the focus of inflammation." .

Other researchers confirmed Spiess' observations, but little use was made of procaine to influence specific diseases via the nerves. It was found that GH3 injections and infiltrations of the ischiatic nerve would stop very painful sciatica attacks, that whooping-cough fits could be controlled by anesthesia of the upper larynx nerve, that lumbago of gynecological origin, muscle spasms, tetanus and muscle atrophies could be influenced by use of procaine. But these were mostly observations, some of them very interesting, none containing any conclusive information.

One practitioner who has used GH3 procaine for more than thirty years most of the time in a combination with caffeine, was Dr. Walter Huneke of Stuttgart, Germany, who with his late brother Ferdinand, of Dusseldorf, was the originator of the so-called "neural therapy," which seeks the cause for most illnesses in foci, and through injections into those foci (inflamed tonsils, bad teeth, operation scars, etc.) is able to clear up a surprisingly great number of morbid conditions. Several years after Prof. Aslan's first report on her findings about the general changes GH3 procaine brings about in older citizens, he said:

"I was struck by these rejuvenating effects GH3. I consider as rejuvenating characteristics restoration of a youthful and fresh appearance, better posture, improvement in skin turgor, in sight and hearing, no more falling out of hair, increase in cerebral functions, such as thinking capacity, memory, sleep, mood, efficiency and elasticity, the increase of sexual and other hormonal functions (return of libido, normalization of menstruation), also an improvement in heart and circulatory disturbances, blood pressure, arthrotic complaints and numerous other manifestations of old age, some of them measurable through the electrocardiograph, blood pressure or metabolism measurements."

Back in 1952, Dr. Huneke in a .published report had commented, almost as an aside, that repeated treatments' with injections of GH3 procaine and caffeine had in many cases "a clearly rejuvenating and therefore lifeprolonging effect." But he did not pursue this course of investigation. This was the job then, left to Prof. Aslan and her co-workers.

WHY A REDISCOVERY?

In a collaboration with Dr. Berthold Kern published a book, «Verjiingung durch Novocain,"* in which he confirms his earlier assumptions, and takes issue with Prof. Aslan because he considers her GH3 injection technique as being too unspecific.)

Procaine has been applied in the following ways:
1. Intravenous injections of 5 to 10 cc of a 1 per cent solution;
2. Drop infusions of 20 minute duration;
3. Local infiltration of 1f2 to 2 per cent solution in doses up to 100 cc;
4. Blocking of the ganglion stellatum by injec tions;
5. Blocking of the sympathetic nervous system; 6. Intramuscular injections;
7. Intra-arterial injections;
8. Various anesthetic procedures.

To list the more than 150 diseases and afllictions against which doctors have reported the use of GH3 procaine by one of the methods enumerated, and with results ranging from complete failure to significant success would make a tiresome catalogue. Positive results from the use of GH3 procaine have been reported in conditions as far apart medically as hypertension and frostbite, colic and fractures, certain eye diseases and heart arrhythmias, some skin disorders, and migraine headache. Its application has been largely on the basis of providing prompt relief from pain, but its therapeutic efficacy has frequently been commented on in the literature.

One of the foremost pharmacologists Professor Fritz Eichholtz of the University of Heidelberg, reached the conclusion that "of old, honest novocain there has become in modern pharmacology a medical substance which seems destined to be the kind of cure-all so many practitioners dream about." When he made this statement (qualifying it by saying that most of the procaine effects are weak and need an additional specific agent) the work of Prof. Aslan had just begun and was not known outside of Rumania.
Pharmacologists, clinicians, practitioners and, lately, gerontologists, have cleared up a great many of the mysteries surrounding procaine. However, as its range of applications indicates, there is much work to be done before we even approach the limits of GH3 procaine's potential; many indications as to its mode of action exist but no definitive conclusions have been reached at this time. Indeed, the more that is discovered about this substance, the more confused the issue becomes. The bibliography on procaine comprises today close to one thousand publications: an immense wealth of information has been spread before the medical profession. Still, there are only a few things concerning this drug with which the entire profession is in agreement.

Despite the fact that GH3 procaine is nonhabit-forming and has been used in the past for treating dozens of diseases, many physicians have been discouraged from using procaine due to reports of its side effects: nausea, vertigo, difficulty in breathing, vomiting, or temporary visual disorders have occurred in some cases, and strong allergic reactions (where an allergy test was omitted) could produce undesirable complications leading perhaps to anaphylactic shock and death.

Most of the negative effects, however, have occurred only during spinal anesthesia; investigations have shown that most frequently in those cases either the dose was too high, or else instead of merely procaine, mixtures with cocaine, pantocain or adrenalin had been used. These regrettable errors have prejudiced many doctors against its use (outside of the field of local anesthesia), and the use of procaine had been on a steady decline since 1952.

Before Prof. Aslan began her experiments, GH3 procaine had never been systematically applied as a general therapeutic measure over a long period of time. She proceeded to do just this, and refused to let herself be discouraged by occasional failures. A slight modification or "buffering" of the plain procaine eliminated the occasional tissue necroses which Prof. Asian had observed in its steady use, made the substance more stable, and seemingly speeded up the reactivity of the body.

Asian's Gerovital, it should be added here, is chemically and pharmacologically different from the standard 2 per cent solution of procaine hydrochloride. It is buffered, i.e. stabilized to a pH of 3.3 to 3.5, thus has a lowered acidity. Its action, according to Asian, is also potentiated by the addition of benzoic acid and potassium metabisulfite.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3


BACK TO TOP

Chapter 10

Some early confirming GH3 reports

Since 1956 news of the GH3 therapy has spread around the globe. Confirmation of the effectiveness of procaine as a treatment for many of the diseases of old age began to accumulate. More and more of the original skeptics have begun their own clinical trials of this therapy, and reports of their work appear in increasing number.

Switzerland

In November, 1957, a group of Swisstologists-Gassman, Jacquerod, Laepple Schaefer-reported on their first clinical trials lows: "The procaine treatment introduced by Aslan was applied in 28 cases; 22 of the patients presented diffuse or localized lesions of the central nervous system: hemiplegia (paralysis), hemiparesis (muscle weakness), spasmodic ataxia (spastic disturbance of muscle coordination), postapoplectic (following a stroke) or arteriosclerotic dementia. Each patient received three 100 mg intramuscular injections a week (5 cc of the 2 per cent solution) in series of 12 injections, separated by ten-day intervals. . . . We obtained lasting results in 25 per cent of the cases, such as improvement of the subjective state, buoyancy of the psychical tonus, slight euphoria, sometimes a better physical tonus in walking and in voluntary motility, and disappearance of sphincteral incontinence."

France

In the Revue Francaise de Gerontologie (April, 1959) Professor H. Portias of Paris, one of Prof. Aslan's early antagonists, reported on his experience with 86 aged patients whom he treated with procaine. Not being able to use placebos, he still endeavored to avoid the possibility of purely psychotherapeutical effects by telling the patients of his inexperience with the method and of his skepticism as to its efficacy. Professor Portias' patients suffered from the usual signs of old age: arterio- and venosclerosis, chronic cough, wrinkled skin, rheumatism, and various arthritic conditions. He subjected them all to five months of procaine injections, at the customary rate of three per week; beneficial effects, except in the less severe cases of senility, could hardly be expected in so short a period. Yet in more than half of the patients the results were either "very good" (15 cases) or they were "improved" (30 cases). Twenty patients felt a bit better, 21 showed no change in their condition, and only three of the 86 showed any side effects which could be regarded as serious.

In the 15 cases in which the results were very good, Prof. Portias noted "a physical and morale stimulation, with a disappearance of all signs of fatigue. The patients experienced a euphoric feeling. . . . disappearance of anxiety and its physical counterpart, fear, an increase in sexual power (the Russians, by the way, treat impotence with intravenous injections of GH3 procaine . . . . These results remained after the treatment was stopped." He also mentions that the cholesterol level of the blood, while initially increasing, soon falls.

Professor Portias' conclusions:

"This is an interesting treatment, happily complementing other geriatric therapies, but no general panacea. For the time being the enthusiasm in Bucharest does not seem to be justified in all cases, even though it is true that our patients were treated for only five months. In any event it seems that the therapy is most efficacious where there exists a clear imbalance of the autonomic (involuntary) nervous system. Another very interesting technique is the combination of procaine with other substances, either simultaneously or following it."

Early in 1959 at a meeting of the Scientific-Medical Section of the International Federation of Deportees in Vienna, Austria, the Parisian physician Dr. E. Soladie reported on his first trials with five deportees whom he had been treating .with procaine injections for several months. He made the following points:

1. The action on the skin is quite obvious; the grey appearance, so characteristic of suffering persons, is disappearing. The face takes on a natural, healthy color, the eyes become livelier. After only four months the hair shows signs of repigmentation and the zones of baldness diminish. Eczemas of different etiology have either vanished or are retrogressing.

2. None of his five patients was constantly tired as before. The irritability diminished, the sleep was bet ter. All had reacquired a desire to work. In four of the five the appetite had improved.

3. Only in one of the five patients was there no effect with regard to sexual functions. In two, there has been a complete revival of libido (in one, after three years of enforced abstinence); in the other two, a normalization of the act.

Germany

In a private talk with the author Dr. Udo Kohler, who was one of the first to undertake clinical trials to check Prof. Aslan's results, revealed that even after giving the GH3 procaine therapy for more than two years, he was still often surprised at the results. He mentioned the case of one of his patients, a dentist, whose hobby was gardening. After the first half dozen injections, this patient asked for Dr. Kohler, who fully expected some complaint. But the dentist, a man in his middle sixties, told him: "You know how I love gardening. But in recent years I have had trouble remembering the names of the different flowers, and their Latin names escaped me completely. Now they have all of a sudden come back." And he proceeded to rattle off dozens of Latin names of the many plants he had in his garden.

More scientific evidence was presented in a case history reported by Dr. Kohler in 1958.

"Dr. G., born February 8, 1877. Symptoms of cerebral sclerosis known for 20 years, accompanied by arterial hypotension. He had been forced to retire from his profession because not only the disturbances as circumscribed by the Korsakov syndrome were apparent, but also increasing vertigo had gained in intensity to such a degree that treatment with GH3 (a German preparation-procaine plus vitamins) was deemed necessary. Objectively the heart muscle did not yet show any indications of considerable myocardial damage. But many extra systoles, particularly after effort, indicated an existing hypoxia of the heart muscle. Paroxysms became so pronounced that the patient would lose his balance in changing from a lying to a sitting position.

"After only the second GH3 injection the patient reported a certain improvement. At the end of the fIrst series, he was virtually without dizziness. Only in the mornings did he still observe slight dizziness-when arising too quickly. Next to the impressive eutrophic skin effect, the most remarkable sign was the return of mental capacities. The old gentleman once again participated in scientifIc forums, and recently-for the fIrst time in over two years-played four-hand piano again. His partner (an internist himself) was quite astonished to fInd that the playing was considerably better than it had been two years previously, when the patient had abandoned the instrument because of his physical defIciencies."

In Medizinische Monatsschrift of May 1959, published in Frankfurt, Dr. F. Petersen, a neurologist from Halle, East Germany, reported on 137 cases of cerebral sclerosis he had treated with procaine over a period of two years (June, 1956 to June, 1958). In 13 of these cases, all symptoms of the illness disappeared; in 35, there was marked improvement; in 56, some I improvement; 27 remained unchanged; and in six cases I there was further deterioration. This means that in 104 I (or 76 per cent) of the cases, treatment by procaine injections was to some extent successful, while other therapies offered little relief for these patients.
Doctor Petersen's figures become even more impressive if one considers only those patients suffering from a state of arteriosclerotic debility. Of the 137 patients he treated, 88 fell into this group, and of these all but four (or 95.4 per cent) were improved: ten were considered cured, in 33, there was marked improvement, and in 41, some improvement of their complaints. Of eight stroke patients, seven showed improvement, and five out of nine patients with Parkinson's disease were also improved after the treatment. Two of the four patients suffering from encephalomalacie (softening of the brain) were also improved. But with his 20 senile psychotic patients Dr. Petersen reported almost complete failure: only one of these showed some improvement, 14 were unchanged and five actually grew worse. His statistics are shown in the table.

In 1962, Professor F.H. Schulz, head of the First Medical Division of the famed Charite in East Berlin, was able to report about animal tests undertaken by himself and his collaborators showing that the procain therapy delayed aging of vascular walls. This could explain why the use of GH3 has the effect of approximating rejuvenation. In later chapters, particularly Chapters 16 and 18, we shall discuss other confirming reports, several of them originating in the United States. American scientists were late in testing this drug but once they embarked on this task, they were able to bring in some very interesting results.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3


BACK TO TOP

Chapter 11

Soviet research with procaine

Not unexpectedly, medical scientists in the Soviet Union have conducted some valuable research into the properties of procaine. In an article in Geriatrics, recently deceased Prof. Chauncey Leake, a former president of the American Association for the Advancement of Science, reported:

"When I was in Leningrad and Moscow in 1956, I discussed the trophic action of GH3 with several experimental workers in the physiology research laboratories in these cities. However, I was not impressed at the time that there was anything very significant in these studies except that intramuscular injections of procaine seemed to have some benefit in experi mental arthritis and perhaps in certain experimental stress conditions. ..

Soviet researchers, naturally, showed a lively interest in Prof. AsIan's work. Theirs has been a steady search for means of rejuvenation, but neither Voronoff (who worked outside of the Soviet Union), Bogomolets, nor Olga Lepechinskaya had any success with their ideas. The procaine therapy was given a great deal of publicity in the Soviet Union, and now there have been several hospitals and old age homes where the treatment was used, in particular at the Geriatric Institute in Kiev.
In Moscow, in 1955, Yu. F. Udalov conducted some experiments with white rats which may have significance not only in geriatrics, but in aviation and space medicine, as well as in prevention of the 'bends' suffered by underwater workers who surface too rapidly.
In U dalov' s experiments, rats which had been given procaine injections in the neck and in the abdominal cavity (as well as rats which had received no injections) were 'lifted' in a baro-cham ber at a speed of 67 miles per hour, to an atmosphere as thin as the atmosphere 6% miles above the earth. The rats were left in this 'atmosphere' for 10 minutes. Six of the 23 control rats died, but only two of the 25 procaine-treated animals. The author then found that rats given a large dose of para-aminobenzoic acid in their food the day before being subjected to these simulated high altitude conditions also had twice the survival rate of rats which had not received this vitamin. Apparently this vitamin component of GH3 increases the resistance of the body to oxygen insufficiency.
An article in the Russian journal Farmakologiia i Toksilkoiogiia (Pharmacology and Toxicology) entitled "Changes in the motor and secretory gastric functions following intravenous injection of procaine" indicates the Soviet interest in this therapy for treatment of gastric ulcers. The article ends with the following summary:

1. Intravenous injection of GH3 depresses or eliminates gastric peristalsis and the periodic contractions of the stomach under starvation conditions; it also depresses the can tractions of the duodenum.
2. Procaine depresses the gastric secretion, particularly in the first 3-hour period and often extending into the second period. Following injection of procaine, the latent period of gastric secretion was increased in most of the experiments. Procaine also depressed the pancreatic secretion.
3. The acid-forming function of the stomach underwent various changes under the influence of procaine, more often than not increasing.
4. Depression of the conditioned reflex of the gastric motor system after a series of intravenous injections of procaine combined with strictly controlled, fixed conditions of experiment indicated the role played by the cerebral cortex in the mechanism of action of procaine.

In addition to their interest in applications of procaine .n treatment of gastric disturbances, Soviet researchers 1Iso are reporting on applications of this drug in treatnent of diseases of the nervous and vascular systems, urunculosis, and bronchial asthma.
The Russian scientists seem to give Prof. Aslan full credit for originating the application of procaine in the general therapy of the condition which we know as 'old age."
Among the Soviet visitors to the Bucharest Institute, Prof. M. G. Durmishyan, of the Academy of Sciences )f the USSR, wrote in Prof. Asian's guest book:
.. After my own investigation, I am able to say that the doubts I may have had before coming here have completely vanished." Professor K. M. Bykov, former head of the famous Pavlov Institute in Leningrad, expressed himself in the guest book as follows:
"With enormous interest I saw the work of the Institute and of Pro£ AsIan concerning a problem which has been studied for a long time, and [the solution of which] could revolutionize mankind. I believe that Prof. AsIan and her assistants have found a valid method of maintaining a normal state of activity of the nervous system and thus of all organs, and of prolonging the normal functions of the cellular system of the human body.
The administration of procaine, which has the properties of stimulating and inhibiting, as well as the method of giving these injections, are new, original and very promising. Personally, I am convinced of the success of Prof. AsIan's method in vitalizing aging organisms."

The intensity of the research being conducted in the USSR on the applications and mechanism of action of procaine is indicated by the fact that in 1958 a Russian book on GH3 treatment of gastric ulcers, bronchial asthma and angina pectoris cites the work of sixteen centers. This research dates back to 1948, and a literature reference shows that the author was familiar with the work being done in Bucharest at least a year before Western medical scientists had heard of it.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3


BACK TO TOP

Chapter 12

News reaches the West

In the Western world, the dramatic story of the successes of GH3 therapy reached the general public before it attracted the interest of the medical profession. In the spring of 1958, a news program of the Columbia Broadcasting System showed a three-minute documentary on Prof. AsIan's work. This short film elicited only a few requests for further information.
My own interest in this therapy had begun when, quite by accident, I accompanied a friend to hear Prof. Aslan's first lecture in Karlsruhe in 1956. As a medical writer, I was of course fascinated by what she had to report-but the antagonism, disbelief, and skepticism surrounding me were highly contagious. I wrote nothing about Prof. AsIan's claims until I received a report from my friend of the great difference between her receptions at Karlsruhe in 1956 and 1957. In December of 1958, Coronet published my first writing on this therapy, in the United States in an article entitled "Old Drug Brings New Hope."
Inquiries began to pour in by the hundreds-to the magazine, to me, and even to the Institute in Bucharest. And these inquiries came not only from old men and women suffering from the very conditions described (and the families of such sufferers), but also from physicians, biochemists, and pharmacologists. . The original research papers on the subject were published in translation for medical practitioners and researchers by Consultants Bureau, Inc., in March of 1959.
At about this same time, the London Daily Mail published a series of five articles by a woman reporter who had gone to Bucharest to learn at first hand the value of this therapy. Her highly sensationalized articles aroused such great hopes and expectations on the part of the aged population of London, as evidenced by the thousands of letters received by the paper, that the series was concluded with a note from the paper's science editor, quoting an unnamed British doctor:

"Old people taken out of lonely or unhappy or disease-prone backgrounds and given expert attention and encouragement in cheerful surroundings often take on a new lease of life.
"Much of the evidence at Bucharest, say visiting experts, may be based on hearsay-patients' ages, previous conditions, and so on. "The same drug used by Prof Ana Aslan has been. tested in this country 'without any startling results'."

To which the science editor added:

"There is no scientific reason known to me why it should cause 'rejuvenation', one specialist told me. On the other hand reasons sometimes come after results, Knowledge of digitalis came after a general practitioner found that an infusion o foxglove did his heart patients good."

On March 14, 1959, a few weeks after the appearance of these articles, the well-known British medical journal The Lancet discussed the procaine therapy in an editorial. It said:

"The cause of the decline of vigor in mammals with age is unknown. There is no a priori reason why GH3, or many other uninvestigated substances, should not slow or even reverse this decline, and a substance which did so would quite possibly produce just the kind of non-specific benefit in a number of disorders which AsIan describes. The regrowth of pigmented hair in a man who claimed to be 110 years old, which AsIan reports, would in any case, like the validity of the age record, excite curiosity. But it is curiosity rather than enthusiasm that AsIan's treatment of her results is likely to excite. Her suggestion that procaine acts by in vivo (inside the body) conversion to p-aminobenzoic acid, and that this exercises a "trophic" action on the nervous system, does not carry instant conviction; moreoever, such an influence (or, in fact, any specific benefit from a drug administered to geriatric patients to control "aging") could be shown convincingly in one way only-by a double-blind trial in alternate matched cases, with subsequent comparison of objective signs and survival curves. All the published evidence so far depends on scientific medicine's chief methodological enemy-the testimonial use of case histories-and AsIan's treatment of these will depress those who know how often medical investigators have misled themselves in this way. There are very few old people who do not respond to rest, change, good hospital food, and, above all, raised morale-whether accompanied by injections of procaine or not. "This is not to say that the work of the Bucharest team is to be dismissed (they have evidently improved their patients in some way, if only by suggestion); and the desire to do something radical about old age is a creditable contrast to fatalism about the effects of age. If these workers were right, the findings would be important. But the facts can be established only by properly controlled trials."

In the United States, publication of the translated reports from Bucharest was not met with indignation, as was Prof. Aslan's first lecture at Karlsruhe. But the reception was, to put it most mildly, unenthusiastic. This lack of enthusiasm was not, as some have suggested, because the new therapy had been developed in a Communist country. It was because the methods of analyzing the results of the therapy fell so far short of American research standards. American researchers feared that the doctor &om Rumania who was making such extravagant claims for procaine therapy had fooled herself, as well as her patients, into believing that they felt and looked so much better.
But there was also a sober recognition that the reports by the Bucharest and German doctors should not be ignored. Prof. Chauncey Leake, who reviewed the translations of the Karlsruhe papers in the journal Geriatrics in October, 1959, said:

"In general, it would seem that the reports by Ana Aslan and her associates are interesting enough for further exploration. It would be hoped that she and her associates would publish more detailed case histories, together with a more complete statistical survey of the large number of cases which they must have accumulated by now. It would seem that careful and direct experimental studies on small animals should tell readily whether or not repeated procaine hydrochloride injections intramuscularly can delay the aging process, prolong life, and generally interfere with aging. It might be wise for results of studies of this sort to be well publicized before extensive premature clinical use of GH3 procaine hydrochloride in slowing the aging process. On the other hand, the safety of the drug indicates that cautious and well controlled clinical studies might yield results that would tell definitely whether or not any further use of the drug for these purposes is justified."

Little can be added to what has been so calmly and objectively pointed out by The Lancet and Geriatrics. Both medical journals have emphasized the necessity that the work Prof. Aslan began at the Institute of Geriatrics in Bucharest be subjected to the most careful investigation on as large a scale as possible, with the use of the most modern equipment available and the most rigid control standards devisable.


Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 13

The Parhon Institute of Geriatrics

It is no exaggeration to classify most homes for the aged as brick and mortar limbos, wherein old people in both physical and mental states of dissolution continue their slow degeneration amid the organized monotony of white bedsheets and hushed voices, broken only by the seventh day visit of an impatient relative. Rehabilitation on this basis is an impossibility, and the most that can be hoped for is constant sedation which will relieve the aches and pains, the discomfort and discontent, the feeling of having been forgotten and the frustration of being able to remember.

Nursing homes, of course, but reflect the prevailing society, as pointed out in 1975 by Dr. Carl Eisdorfer, chairman of the Department of Psychiatry and Behaviorial Sciences at the University of Washington School of Medicine in Seattle. About one million out of twenty million aged in this country are in full-term custodial care-as the U.S. Senate's Special Committee on Aging stated in a report a few years ago, this care, or rather non-care, is costing taxpayers close to five billion dollars a year through Medicare payments to nursing-home owners.

This is not the place to discuss whether such money could be spent more wisely although the evidence would indicate so, or whether it is enough. If, however, we wanted to save money, Prof. Eisdorfer suggests facetiously, we would only have to follow Kurt Vonnegut's idea in Welcome to the Monkey House. "He handles the aging problem very simply.

He pictures, next to some restaurant, such as Howard Johnson's, a parlor where people can go between their sixty-fifth and sixty-sixth birthdays and have their lives terminated. Vonnegut's parlor is staffed by attractive men and women skilled in discovering the best method to do away with people. Sometime before a person's sixty-sixth birthday he walks into this future Howard Johnson's, gets a free meal, then walks next door and, against a background of soothing music, has the death of his choice."

What we have to do, of course, is finally to recognize, why older people are with us and why, even in a country as youth-oriented as ours, they deserve the best possible care, free from indifference, neglect and exploitation. It is an indictment of our society that we are still years away from attaining this goal while elsewhere and even in some poorer countries considerable progress has been made in that direction.

Each of the patients in the Bucharest old age home was, at one time, debilitated, plagued by sickness, and steadily growing weaker in mind and body. Today, not one of the patients who has received the GH3 therapy is bedridden! That in itself is a remarkable achievement. However, the procaine-treated patients not only walk about unaided; they also function as alert, thinking, industrious men and wome.n who are old without being aged. Almost every one of them has a task: some work in the kitchen, others in the garden; a few are busy carpet weaving, others make handicrafts, and some help in the library. And, most significantly, many of them even atteI1d courses in French. The procaine therapy has helped them to remain mature while they grow older.
The research upon which the whole therapy is based was begun in the Institute in May of 1951. Twenty-five patients, ages 60 to 92 (all of whom suffered from serious degenerative diseases such as extrapyramidal disturbances, hypertension, degenerative joint disease, rheumatism, cirrhosis, etc.), were treated with procaine. After some initial uncertainty, Prof. AsIan arrived at what she believes is the optimal dose and strength for the procaine: intramuscular injections of 5 cc of a 2 per cent solution, three times weekly for four weeks, were administered. A ten-day interval without further inoculation followed, then a new series of twelve injections, another interval, and so on.
Before treatment was started, possible allergic reaction was tested for with an injection under the skin of 1 cc of GH3 procaine. Few people were found to be sensitive to this substance-in Bucharest only a handful among the thousands of patients (four out of the first 4,800 tested). It can reasonably be expected, however, that a higher allergy rate may be found in the West, where sensitization generally is greater and allergic disorders affect more people than in Eastern Europe.
Sixteen of the 25 old men and women in Prof. Aslan's original group were still alive eight years later, in spite of the fact that the disorders from which they had been suffering (as stated above) would ordinarily have claimed the lives of almost all of them. There was not a single death during the first two years of treatment. In 1954, there was one death due to a spinal accident; in 1955, two deaths occurred, due to chronic bronchitis and myocarditis (an inflammation of the muscular part of the heart wall); in 1956, one death due to a pseudobulbar syndrome, from which this pa.. tient had suffered for six years. Five patients died in 1959-three in a flu epidemic, one due to arteriosclerosis, and one due to an accident.

The number of patients receiving GH3 procaine therapy was slowly increased after the successful results with the first group tested. In 1959, when twice I visited the Institute, 70 of the patients in the old age home received procaine injections, 40 other inmates were used as control group. The table indicates a portion of the impressive results obtained.

The mere prolongation of life was of minor concern to the Bucharest doctors. (Indeed, most of the patients there had already achieved an enviable record of longevity.) Instead they were interested in developing a method of the preservation and restoration of vitality. Thus, the figures indicating the improved capacity of the procaine patients to do some work and to care for themselves are much more significant than the dramatic figures on mortality. These exciting statistics are shown graphically in the photo section (pp. 80 -94).

When I first walked among the patients at the Bucharest Institute, I was struck by the fact that some seemed to be merely well preserved, active people for their apparent age, while others had a strikingly vital appearance (I hesitate to use the word 'youthfull a reader misinterpret and think I am implying that some of the patients had grown younger). All of the patients, including those who had been receiving procaine more than 100 times a year for eight years, remained old people. But those who had been on GH3 procaine therapy for some time had a look of vitality that one might characterize as 80-years-young," or even 112-years young" in the case of Parseh Margosian.

Until the flu epidemic in 1958/59, the mortality of the patients treated with GH3 procaine was 3.2 per cent (and the median age 82 years), that of the people treated with vitamins or gland extracts was 16 per cent, and of those who did not receive any supportive therapy, 27 per cent. Since the patients themselves did not know what treatment they were receiving, the great difference in the mortality of these groups contradicted those critics who ascribe the success of the procaine therapy to some suggestive effect.

The Institute of Geriatrics was founded in 1951 to study the problems of gerontology and geriatrics, as part of the research plan of the Academy of the Romanian People's Republic, thus constituting a portion of the State Scientific Program. Therefore, it is important to note that Prof. Aslan was not, as were most of her predecessors in the application of GH3 procaine, working on an individual basis with the goal of personal symptomatic relief.
Over the years, the Institute of Geriatrics has constantly widened its scope and since 1957 many thousands of people, have been treated on the premises stationary or on an out-patient basis, and, in the case of foreigners, "at the Hotel Pare in Bucharest as well as in two other centers at the Black Sea and in the Carpathian Mountains. (Procaine cures today are also offered by sanatoria in Italy, Spain, Germany, Mexico and even in Egypt.)

In 1972, Prof. Aslan reported to a Congress on Gerontology in Bucharest that during the preceding two years 15,000 people, aged 40 to 62, had been tested at 144 centers in Rumania in order to find out whether GH3 would not only prove an anti-aging factor in the aged-which she felt had been borne out by the research and the results up to that date-but whether it might also prevent aging. Of the 15,000, more than 7,000 were selected for treatment which was identical, except that 4.021 persons received over the two-year period 10 series of 12 Gerovital (the Rumanian procain) injections while 2.905, acting as control group, did not. The results of this large-scale experiment were significant in several respects: High blood pressure improved in 85 per cent of the procain treated and only in 61 per cent of the control patients; arterial hypertension showed signs of normalization in 83.2 per cent of the Gerovital-treated and 65.8 of the control patients; the pulse rate in persons with tachycardia (a rate of over 90 beats per minute) normalized in 93 per cent of those getting GH3 Gerovital but only in 88 per cent of the control group, of those with brachycardia (low pulse rate) the normalization in the Gerovital-treated group was 9 per cent higher than in the control group. With respect to cardiovascular effect, muscle strength and respiratory capacity there were also greater normalization rates in the Gerovital-treated persons where some abnormalcy existed. Hardly less exciting was the finding that in the course of the two years when due to aging, higher blood pressure and more tachycardia might have been expected, there was no change whatsoever in the normal, Gerovital-treated persons. Also, the number of days the Gerovital-treated persons remained off the job for reasons of health diminished nearly by two fifths, compared with the years before treatment took place. These figures would indicate a strong prophylactic effect of procaine; only when this long-time trial has been terminated in 1980 and the findings published, will it become possible to grasp the full importance of this previously unexpected results of procaine.
Already as a result of the initial success with the procaine program, the Institute had become physically larger and scientifically a more important place. It is composed of six departments:

1. The nursing home where aged people are cared for under the conditions cited previously. Long-term treatment is provided here.
2. The clinic for the treatment of bedridden aged patients as well as others affiicted with certain diseases which respond to procaine treatments. In this section, the emphasis is more on short-term treatment.
3. The out-patient department, where procaine treatments are administered daily to hundreds of persons, some for therapeutic and other for prophylactic purposes.
4. The laboratories: some for animal experiments, others for clinical, physiological biochemical, hematological, pharmaceutical and roentgenological research. Each of these laboratories is under the direction of a specialist, some of whom are visiting experts from Rumanian Universities.
5. The department of social hygiene, which is mostly concerned with the sociological problems of old age and relates national statistics to the work of the Institute.
6. Three additional facilities for the treatment of foreigners. Because the Institute will continue to treat, as well as to investigate, it is distinguished from almost all other existing centers in this field, most of which are devoted exclusively either to the care of the aged or to research into their problems.
"Before and after" pictures are convincing to the medical scientist only when it is obviously the patient who has changed, and not merely the angle of photography, the lighting, or the type of film used.
The four pictures of Maria Tabarcea shown in these pages are excellent documentation of her case history. The improvement in the condition of Tanasalu Mircea is obvious, in spite of the difference in lighting. But as medical documentation, the other photographs of patients are "not entirely satisfactory."
Professor Ana Aslan, M.D.

Today at 80, she still guides the destiny of the Bucharest institute which she has headed for more than a quarter century. Last year alone she traveled to Africa, Asia, the United States and to several European countries, delivering lectures, consulting, treating patients.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3


BACK TO TOP

Chapter 14

GH3 Procaine therapy at the Institute

The hospital division of the Institute has slowly expanded as it became apparent that a number of diseases which required hospitalization could also be treated through long-term procaine injections. As a matter of fact, increasing numbers of children are brought to the Institute's hospital or to its out-patient clinic for the treatment of such disorders as skin diseases, osteoporosis (enlargement of bone marrow), bronchial asthma and rheumatism.

There are also rare cases of alopecia (or baldness) and vitiligo (the loss of pigmentation in skin or hair, making it appear white, which can occur in children and young adults as well as people of more advanced age). The great majority of the patients being treated with procaine today are out-patients. They are under constant observation, but of course cannot be controlled as carefully as the inmates.
The treatments for patients of the Institute, how ever, have become standardized.
The GH3 procaine used has been modified over the years. While it originally had a pH (hydrogen exponent) between 4.2 and 5, this has now been reduced: to 3.3-3.5 in the Rumanian preparation called Gerovital or "H3," produced according to Prof. Aslan's formula. (A substance at a pH of 7 is neutral-neither acid nor alkaline, but below 7 it becomes acid.) Experiments proved that if the pH of GH3 procaine is augmented, its anesthetic properties are increased; conversely, if the pH is reduced, it loses the anesthetic properties, while the action on the sympathetic and parasympathetic nervous system is preserved or even increased. The lowered pH may have something to do with the fact that, in Bucharest, side effects have almost never been encountered, and that allergic sensitivity to the stabilized substance is almost nonexistent.

Intramuscular injections of procaine are the rule in this treatment, but there are a few exceptions. In cases of asthma, gastric or duodenal ulcers, and vascular spasms, intravenous injections are considered more effective, and in arteritis as well as certain arthropathies, . intra-arterial ones are indicated. The rhythm of injection is also slightly changed: in vascular spasms, 5 cc is given twice daily; in ulcers, 5 cc is given once daily at a very slow rate. The usual series of twelve injections with a rest period of seven to ten days is constantly maintained, however.
The 5 cc dose of procaine is reduced only where body weight of the patient is abnormally low; in these cases 3 or 4 cc are recommended. Children, as a rule tolerate the 5 cc dose well. In the prophylactic treatment of old age, dealing with people between 45 and 60, the cycle of twelve injections per month is observed, but one or two series per year suffice, whereas in the geriatric clinic, procaine is given as a maintenance dose. The prophylactic treatment, as mentioned will have to be continued for several more years before significant statistical data can be obtained.

As further proof of the fact that one does not develop a tolerance to procaine, it is important to note that even among the survivors of the original group which Prof. AsIan has worked with and treated for more than eight years (they received more than 1,000 injections), higher doses are not needed in order to achieve the desired effects. Nor has a sensibilization for procaine been noticed.

There is only one positive contraindication of the procaine therapy (with the exception of the allergy, of course), and this is the simultaneous administration of sulfa drugs. Here, procaine acts as an inhibitor. If plain procaine is used for the treatment, the patient should, as a precautionary measure, rest for about half an hour after the intramuscular injection. Longer rest periods are indicated in cases of intravenous injections. Procaine has a dilating effect on the blood vessels, causing a lowered blood pressure, which in turn can produce untoward side effects. When a buffered form of procaine is used, however, there is no need for rest after the intramuscular injection.

Other GH3 procaine preparations of slightly different compositions have been developed in other countries and their number is constantly on the increase since the oral procaine therapy has been introduced. But for all these pharmaceutical products, produced in many countries, the therapy prescribed follows closely the plan developed by AsIan although changes had to be made once procaine capsules and dragees were introduced, making the application much easier since it was then no longer necessary to visit a doctor thrice a week.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 15

From Gerovital to K.H. 3 to GH3

Once Dr. AsIan had reported her successes with the injectionable procaine preparation Gerovital, there was little doubt that much as older people had to profit from this therapy, it would more or less have to remain restricted to stationary treatment as was the case in Bucharest where, in a country with socialized medicine, the state was to foot the bills.
In the Western countries the situation was different, and the impetus to find a more convenient application came from Germany where, more coincidentally than intentionally, AsIan had first announced her treatment for older people in 1956. The easier application, of course, meant a pill to swallow, and as early as 1959, the first one, Gerovital plus GH3, came on the market.
Since then, more than a score of such preparations are being sold in Germany alone. The leader in this field became K.H.3 (the "K" stands for Kapsel, German for capsule), and its manufacturer, Schwarzhaupt in Cologne, is one of the few German companies which also continued research in this field. Today GH3 is produced in, and exported to 78 countries on all continents.

All of these preparations contain as primary ingredient procaine hydrochloride but its quantity varies from 12.5 to 70 mg per capsule. As in the case of Aslan's Gerovital, they also contain other ingredients although the rationale for such additions is not always clear and at least in some instances they seem to be no more than devices to distinguish their product from those of their competitors. Most contain Vitamin A, C and E plus those of the B complex, at least one has homoeopathic doses of dried testes, ovaries and corpus luteum and some have hematoporphyrine added, a substance which works as a catalyzer and is supposed to potentiate the effects of procaine in bringing about a physical and mental activation of the patients.

In Germany as well as in most other countries, all GH3 capsules are over-the-counter items and can be dispensed without a prescription since the safety of procaine has been established; also, in the more than twenty years procaine has been used by millions of people, no untoward side effects have been noticed. Most oral therapies follow a somewhat different course from the original one established for the injectionable substance: usually one capsule should be taken daily for 30 days, then, after a 10- to 14-day interval, another course is started, etc. Some manufacturers suggest only two thirty-day series per year, others recommend more than one capsule per day. Physicians with some experience in the field feel that once patients have reached a certain age, say 70 or so, one or two series of injections per year added to the oral preparation will increase the efficacy.
Some of the German procaine substances (with the quantity of procaine in mg added in paranthesis) are the following in alphabetical order: Aktis H 3 (50), Biolecit H 3 (25), Dodecatol (50), Echtrovit (50)~ Genuol (50), Geriatricum Pascoe (12.5), Gerigoa Depot (45), Gerioptil plus H 3 (25), Gerontin Kwizda (50), Glutergen + H3 (50), H 3-Quam (25), Ilja Rogoff Gold (50), K.H.3 Geriatricum Schwarzhaupt (50), Panganicain (25), Panstabil (50), Primarubin (51.2), RecapsDepot H3 forte (70) Roleca H 3 (25), Vigodana (30), Vivioptal (55), and Zellaforte plus (46).
While Germany produces more GH3 preparations than any other country, it is by no means the only one. Although a great many have been discontinued, we are aware of indigenous products in Switzerla,nd, Greece, Great Britain, Spain, Argentina, Brazil, Ecuador and Mexico. The total output is anybody's guess.
Today there is general agreement that the oral GH3 therapy, while perhaps not as efficacious in acute stages, makes it so much easier to use it prophylactically-before people are aging. Even Prof. Aslan, who for many years was a champion of injection therapy, finally was convinced of the value of an oral preparation. First named Aslavital the pills reverted later to Gerovital H3, the same name used for the solution; in Germany it is marketed as Gero-H3-Aslan, containing a larger dose of procaine hydrochloride, namely 100 mg. Of course, ampoules continue to be sold; they are used in most clinical trials which have also begun in this country and we shall deal with them in a later chapter. Here its name has' been simplified still further to GH3.
What may have changed Dr. Aslan's mind as to the usefulness of the pills were perhaps the many papers published in medical journals about the successes with K. H.3. As already mentioned, its producer was the only one to sponsor clinical trials on a larger scale, and scientists from several European universities as well as physicians added valuable information to that which continued to flow from Bucharest. Unfortunately, in the West we do not have an institution as well geared to old age treatment and research as Prof. Asian's Institute which she continues to guide although she is now past 80, thus experimental as well as clinical work is widely scattered.
What we did learn from the reports about treatment with GH3 duplicated basically what AsIan and her collaborators had found as a result of the parenteral method. All told, more than fifty papers have become available, some in the United States, covering various aspects of KH 3 therapy. Not all are double-blind tests, as required in this country but, as we mentioned earlier, are not yet generally demanded in Europe. The patients covered in these papers were also for the most part ambulatory, thus not as easy to control as bedridden or institutionalized patients. But a number of double-blind control tests did take place; thus-to mention one-Prof. E. Pakesch of the University of Graz, Austria, reported on the treatment of 100 patients, 72 over, 28 under 65 years of age, after a stroke. He stated: "Of the 72 patients over 65 a therapeutical success in the sense of activation was observed in only 26; the other 46 showed no change. This negative experience is corrected, however, when we distinguish between drug and placebo. While of the 26 patients, in which we were able to observe an improvement, 23 had received GH3, of the unsuccessfully treated 46 patients 36 had received the placebo. . . . The results of the double-blind control test and their statistical evaluation suggest that in patients with apoplectic insults and pronounced psychological rigidity over the age of 65, mainly due to senile arteriosclerosis, therapeutical effects can be obtained with GH3 In this group of patients a placebo effect of GH3 can be excluded."

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 16

GH3 in the United States

Despite the denunciations by the British Medical Journal (Prof. Aslan is a "woman gifted with humor, charm, enthusiasm and boundless therapeutic optimism but she had failed to meet the necessary scientific requirements... before any claims could be made"), and the American Medical Association in the Journal of the American Medical Association and elsewhere, GH3 refused to go away. In England, recognition came relatively fast: as early as 1966, the Dunlop Committee on Drug Safety (in certain respects the counterpart of our FDA) had it cleared for general distribution. As in most other countrjes it is available in English pharmacies without a doctor's prescription.
The FDA mills worked considerably slower. It was not until 1970 that animal experiments to prove the drug's safety were approved and clinical tests did not get under way until May 1972 and were then restricted to only one indication: depression. The first reports by reputable scientists were so positive that the drug's fmal approval seemed to be close. Just when this was expected several news articles appeared implying that GH3 was influencing the aging process. Immediately the FDA asked for proof that indeed it did prevent aging-obviously something that could only be proved clinically in many years' work. Then the FDA reversed itself once more. The Rom-Amer. Co. which had tried to get the Rumanian drug approved, ran out of steam. The many years of waiting and carrying out costly testing, had eroded its financial basis.
Melvin Krattar, a Nevada businessman, who had taken H3 in Europe to help him fight depression following life-threatening heart surgery, bought the company late in 1976. He lobbied the Nevada legislature to let H3 go the "Laetrile" way and legalize manufacture and sale in Nevada. (Laetrile, an anti-cancer drug, also banned by the FDA, over the last year has been approved by the legislatures of fourteen states, and 24 more are considering such action in 1978. A Federal judge in Oklahoma has even decided that the FDA has no right to bar access to this drug to a terminal cancer patient thus, for all practical purposes, legalizing its use nationwide-provided his decision will not be overturned by higher courts.
Kratter then discontinued the promising tests, withdrew the pending FDA application and made preparations to dispense the treatment in Nevada. At this writing no one knows whether Kratter will be successful in attracting enough people to the Sagebrush State to make his gamble pay. The foot, however, is in the door, and theoretically at least, other makers of procaine preparations could also use Nevada as their American base, hoping to convince other state legislatures to follow Nevada's lead, as in the case of Laetrile.
In the press it was reported that Daniel J. Demers, majority leader of the Nevada State Assembly, declared: "The evidence in support of GH3 was simply overwhelming-from doctors, clinicians, pharmacists and patients throughout the United States." One of the doctors quoted was Dr. Abraham H. Rudnick, a Las Vegas cardiologist, who stated that he had used GH3 on thousands of patients.
People suffering from depression, a frequent concomittant of old age, when taking GH3 are "more at ease, more rested, more able to cope with events in their lives," said Rudnick. "They are less preoccupied with aches and pains. It improves their mental psyche. "
Dr. Keith S. Ditman of the Vista Hill Foundation in San Diego reported on a GH3 test with 170 patients of whom "the vast majority" showed a higher sense of well-being, more energy and relaxation, and improved sleep.
The FDA, at least momentarily outwitted, has already threatened action should raw materials for the drug be brought into Nevada from outside the state or some of the finished product taken out of Nevada. That the agency might not shy away from such action, can be deduced from its attitude towards Laetrile: In Wisconsin and Tennessee according to science writer Lee Edson, writing in the New York Times Magazine, "its agents recently swooped down on several farmers and confiscated sacks of (apricot) pits," out of which Laetrile is being made. "The FDA asks apricot growers to inform them of what seems to be illicit apricotpit traffic, and has been reported to use helicopter surveillance against the enemy pit."
The reluctance of the FDA is not easy to explain, but there is no doubt that this agency is criticized by the pharmaceutical industry for being too cautious and by consumer advocates to be in cahoots with the in dustry it is supposed to regulate. Both sides can marshal enough evidence for their point of view. But the fact of the matter is that today it takes from six to eight years and many million dollars to get a drug approved for sale in the United States.
In a recent magazine article the Noble Prize-winning economist, Dr. Milton Friedman of the University of Chicago, stated: "The FDA has done more harm than good. The reason is very simple-no Food and Drug Administrator has ever been pilloried for not approving a drug which was potentially capable of saving many lives."
Prof. Friedman continued: "Any Food and Drug Administrator is bound to be pilloried for making the other mistake, namely, approving a drug which turned out to be harmful. As a result, the Food and Drug people have a bias in holding up good drugs in order to avoid the possibility of mistake in approving a bad one. The result is that there are many effective drugs which are available in Canada, in Britain and elsewhere which cannot be purchased by people in the United States, but which might very well save their lives. ..
Could it be that the procaine preparations are among those drugs Prof. Friedman has in mind? And if so, what can now be done after the most promising test series has been discontinued, to bring about their availability in this country? No answer can be given to this question, but in the absence of affirmative action by the FDA we will now briefly survey the results of various tests undertaken in the United States. The first papers in this country reporting successes with procaine came in the sixties. Psychiatrists Luigi Bucci and John C. Saunders found in 1960, in a study of 25 psychotic women that procaine is "effective in alleviating depression and reducing psychotic symptoms associated with schizophrenia." Four years later, also in the Journal of Neuropsychiatry, psychologists Dr. Solveig S. Gislason and Dr. Robert F. Long reported that procaine "improved performance in orientation, attention and memory" in 33 totally disoriented patients.
Only in recent years when, under the overall supervision of Dr. Nathan Kline, Associate Professor of Psychiatry at the Columbia University College of Physicians and Surgeons, the systematic testing of GH3 with a view of gaining FDA approval began, did new reports on the efficacy of the drug in fighting geriatric depression come in. Kline himself said that neither in 40 humans nor in rats given up to 60 times the optimum dose of procaine had any side effects occured.
The general impression was that most of the patients improved as the treatment went on but no attempt was made in this phase of testing to evaluate the results statistically. Two additional studies were undertaken at the Duke University Aging Studies Center in Raleigh, N.C. Two trials were undertaken with the same group of 30 patients, nine of whom received Gerovital H3, eleven the standard antidepressant imipramine and ten a placebo. All were "mildly ill" with depression, and the average age of the three groups was 67.2, 68.4 and 68.7 years, respectively. Dr. William Zung, professor of Psychiatry, reported that five ratings were taken to assess the progress of the patients during a 28-day course of treatment. On the self-rating depression scale and the self-rating anxiety scale GH3 worked considerably better than either the other drug or the placebo while in'the other three there was no statistically significant difference.
In the second Duke study Prof. H.S. Wang examined the effects of GH3, imipramine and a placebo on various neurophysiological criteria and found no great difference in the effects of GH3 and imipramine but thought that the former might be safer for elderly patients.
The same ratings as in the Duke University trials were used at the Desert Hospital Mental Health Center in Palm Springs, CA in testing 33 patients on GH3 and 30 on a placebo. The Center's director, Dr. Max Kurland reported, according to Medical World News, "we got some very positive results. They were statistically significant for all five evaluations we used." Other investigations were carried out at the University of Southern California in Los Angeles and at McGill University in Montreal.
That's where the matter rests for ,the present since all tests have been discontinued. Except for one other quite important contribution: Observing the effects of procaine on the aging, no one knew much about the mode of action of this ubiquitous drug. At the annual meeting of the Gerontological Society in Miami Beach, in November 1973, two investigators from the University of Southern California reported on their independent research concerning the mechanism of pharmacological action of GH 3. Professor M. David MacFarlane found that GH3 alters the activity of an enzyme essential to the control of brain function, monamine oxidase or MAD. This enzyme controls the rate of destruction of essential compounds, so-called neurohormones in the brain, nerves, and other human tissues. Its activity increases progressively after age 45. As the levels of MAG activity increase, the rate of destruction of the neurohormones results in lower neurohormonal levels.
The consequences of this age-related phenomenon include severe mental depression and decreased mental acuity. By inhibiting the elevated activity of MAG in older persons, Dr. MacFarlane said, GH3 decreases the rate of destruction of the brain neurohormones and allows depressed levels of these substances to return more toward normal. This, in turn, helps restore brain functioning. Although we know of other drugs as MAG inhibitors, their use has resulted in severe and sometimes fatal side effects, while adverse reactions to procaine, as previously noted, are almost non-existent. Josef P. Hrachovec, a research associate at the Andrus Gerontology Center of the University of Southern California, reported at the same meeting about his investigation of the basic mechanism of procaine's activity in isolated tissues and in experimental animals. His findings show that GH3 inhibits MAG activity in the brain, liver, heart, and in blood platelets.
Interestingly enough, other MAG inhibitors have similar effects as the procaine preparations. Both are useful in the management of hypertension, angina pectoris, arthritis, depressive states and schizophrenic episodes. With MacFarlane's pharmacological rationale seemingly well established, it may now be possible to find the common denominator for the many effects of procaine, KH3, GH3 and all the rest, which until now have been puzzling even to well-meaning investigators.
Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 17

A rehabilitator for the aged

As we have mentioned previously, procaine acts on many parts of the body. Clinical observations lend credence to the findings that GH3 procaine affects almost all those organs, glands, and functions that. are.p~..r!icularly deficient in old age. It is important to bear in mind that most of these conditions are of a chronic nature and require long-term treatment. Many of the failures with certain applications of the procaine therapy may stem from the fact that the treatment was not applied for a sufficiently extended period of time.
The data in the table cover a significantly large number of patients at the Institute who were treated during the years from 1952 through 1958: for a variety of diseases. Again, the statistics on improvement are much more convincing than those showing a lower mortality rate as compared to patients not treated with GH3 Procaine.
What kind of diseases yield best to the GH3 procaine therapy, quite apart from the general improvement noticed in the patients? The statistics in this table indicate that diseases affecting the skin and hair, as well as the wide circle of ailments connected with the central nervous system, are most responsive. Among the former we find eczemas of different etiology, alopecia, herpes zoster (shingles), psoriasis, vitiligo, ichthyosis and scleroderma, to name but a few where some experience has been gained. Among the latter gratifying results have been achieved in post-apoplectic situations, paralytic states, neuralgia and neuritis, Parkinsonism, Burger's disease and multiple sclerosis. The application of procaine therapy is also fruitful in degenerative joint and bone diseases, such as arthritis and the different arthroses, osteoporosis, and Bechterew's disease.
Before we discuss the various theories as to how procaine acts on the various parts of the body to affect the diseases which attack these parts, let us first examine in more detail the extent to which the body and its diseases are affected by GH3 procaine therapy.

Chapter 18

Diseases of the nervous system

The effects of procaine GH3 on the nervous system appear relatively fast, and are clearly noticeable. The disorientation and confusion which is so often characteristic of old people disappears, and memory, perception and ability to concentrate are renewed. In younger people under treatment these mental functions seem improved as compared to their capacities before treatment with procaine. Shortly after treatment is initiated most old people show an increased desire to live: they display better moods, their eyes become increasingly bright, and their hearing (and occasionally their vision improves. This indicates that procaine injections produce an immediately increased response to stimuli. Perhaps the ganglions of the diencephalon (interbrain are affected, leading to an improvement in walking ability, to a better mobility of the fingers, and to a decrease in so-called extrapyramidal rigidity (characteristic of Parkinson's disease and other illnesses in which muscles stiffen and the expression of the face becomes mask like ).

According to Prof. Aslan, procaine GH3 has a neurotrophic action (supplies the nerves with nourishment) not only upon the central nervous system, but also upon the peripheral nervous system, which would explain its effect upon a great variety of diseases. Italian researchers have found that procaine exerts a direct action on the brain; after intravenous injection of procaine in animals, they found the largest quantity of it in the brain. Russian physiologists have also confirmed the direct action of procaine on the nervous system.

Studies in Bucharest have shown that it is within the highest age brackets that neurological diseases are by far most frequent, whereas cardiovascular and rheumatic diseases are the main problems in advanced middle age. In view of these findings it is particularly important to note that procaine also affects the peripheral nervous system, as evidenced by a cessation of neuralgia and a decrease in neuritis, both of which are very painful conditions frequently present in elderly people.

Conditioned reflexes also are improved under procaine therapy. After prolonged treatment older people are able to fix their reflexes after only three associations, which is the rate generally observed in young people and adults (usually, in older people from nine to twelve associations are required). No similar improvement was noted in the elderly patients who were treated with any other substances, with the exception of thyroid extract, which has a slightly stimulating effect upon the central nervous system.

Thus far, there is not enough experience to reveal the whole potential of procaine therapy in special neurological cases, nor has the method been sufficiently refined to ensure the quickest possible recovery of the patient. Prof. AsIan's technique is nonspecific (stimulating the entire organism, and thereby indirectly influencing the ailment instead of attacking the specific ailment directly).

Multiple sclerosis

A case in point is multiple sclerosis, a disease still considered incurable. Prof. AsIan does not claim that she is able to cure it. Still, the fact that she has been able to achieve considerable improvement in her multiple sclerosis patients (with many series of procaine injections) is undeniable. Again, the use of GH3 procaine in Multiple Sclerosis is not quite new, and this fact underscores Prof. Aslan's repeated statement that hers is not a discovery, but a rediscovery.

We should also note that there are periods of spontaneous remission of this disease, usually followed by a worsening of the condition.

In 1950, the noted West Berlin surgeon Erwin Gohrbandt reported dramatic improvement as well as cures of multiple sclerosis with procaine injections into the sympathetic. trunk, in particular into the stellate ganglion and the solar plexus. By 1951 he had treated 87 persons, and in a few advanced bedridden cases freedom from all symptoms had lasted for three years, which is considerably longer than the usual periods of retrogression of this disease. He also noted, however, that the stage of the illness at which procaine treatment is begun seems to determine the possibility of success.

Parkinson's disease

As early as 1919, Dr. G. Liljestrand described highly promising results with procaine in the treatment of Parkinson's disease, but no subsequent reports were made. It was not until more than 35 years later, when Prof. AsIan reported her success in reversing the Parkinson syndrome (rigidity of muscles, tremor of the arms and hands, loss of associated and automatic movements, masklike facial expression), that the earlier paper was remembered. In the years preceding Prof. Aslan's resdiscovery of GH3, no one had paid any attention to the 1919 paper.

Postapoplectic conditions

Another rather important application is the intravenous injection of procaine in cases of apoplectic coma (unconsciousness after cerebral stroke). The patient is usually brought back to consciousness quite rapidly and this status is maintained from 30 minutes to several hours, depending upon the severity of the attack.
In any event, there is sufficient time in which to feed the patient and thus banish the danger of aspiration pneumonia (caused by foreign bodies being drawn into the lungs while the swallowing center is not functioning). This latter complication cannot be fought even with antibiotics.

Loss of hearing and GH3

A very interesting experiment was conducted by Dr. P. Braunsteiner, of Rheine, Westphalia, Germany.
This physician confined himself to the observation of a group of elderly hard-of-hearing patients. He chose 35 people over 55 years old, and subjected them to several series of GH3 procaine injections. All reported feeling generally better, and gave evidence of increased auditory acuity. Audiometric measurements showed that in 13 of the patients the improvement in acuity was strictly subjective-they were all over 70, and probably had already suffered irreversible damage to the nerve cells. In the other 22, the improvement could easily be verified by the usual methods and the audiogram showed an increase in acuity of 15 to 30 decibels.

"This audiometric proof is clinically very interesting," Dr. Braunsteiner reports, "but we feel that the subjective improvements is of larger practical importance. This subjective improvement without exception is greater than compatible with the audiometric results. The reason must be looked for in the effect of Gerioptil (a West German brand of procaine) on the general condition of aging people. All patients feel more vigorous, mentally as well as physically, their memory is improved and the general interest in their surroundings has increased. Consequently the power of concentration and receptivity has also increased, and with it the perceptive faculty of the ears. An examination of the acuity for voice showed an average increase in hearing power for conversational speech from 2 to 3 meters, and quite frequently even 4 to 5 meters. The perceptivity for whispering was only slightly improved."

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 19

Diseases of the muscles, joints and GH3

The aches and pains which plague so many of the aged are . usually connected with either the muscles (particularly the legs and hands) or the joints. GH3 procaine has been found to be highly effective in relief of such pain by many workers, and its therapeutic effects on these conditions were noted long before Prof. Aslan began her work.

Rheumatism and arthritis

As we mentioned earlier, Gustav Spiess was the first to point to GH3 procaine as an antirheumatic agent. However, he did not pursue his original observations, and they were soon forgotten. It was not until the nineteen-forties that Dr. M. G. Good of the Charterhouse Rheumatism Clinic in London championed procaine treatme.nt for his patients. In this country, Dr. David J. Graubard, of New York City, devoted himself to its’ application, and wrote extensively about it.

The effect of procaine on the joints was the point of departure for the present therapy. Successes were perhaps less pronounced than in other areas for which procaine therapy was indicated, although, in the words of Dr. Good, "the results of procaine treatment (in rheumatic conditions) would be hard to match or surpass by other methods of therapy." Frequently, the mobility of the joints is restored, the pain alleviated, contraCture of muscles decreased, and the muscle power strengthened. Prof. AsIan reports that X-ray pictures sometimes indicate remineralization of the bones, which may be the reason why fractures, seemingly, heal faster with procaine therapy. Prof. AsIan herself is a good case in point. A few years ago when past 70, she had a severe car accident, suffering multiple fractures of legs, arms and neck. With the help of GH3 she made a relatively fast and complete recovery, and today, although past 80, no trace of the fractures are noticeable.

In a lecture before the Congress of Internal Medicine in Paris, in September, 1950, Dr. Good described his successes in treating muscular rheumatism as "Well as arthritis with intramuscular injections of procaine (a technique little used heretofore). In rheumatism the pains are concentrated in the so-called "myalgic spots," which are also very sensitive to pressure. His report covered 80 cases, and

". . . . the therapeutical results were brilliant, often dramatic and wonderful. A permanent cure can be forecast with great probability, if not positive safety. In clinical medicine there are few therapeutic measures which allow more impressive and dramatic successes: a patient, for instance, who is suffering from an acute attack of lumbago. . . . and complains about unbearable pains, can be freed from his complaints, as with a wand, within a few minutes through the injection of 5-10 cc of novocain. This method was tried out in the British Army during the war in many cases, and found to be very successful."

\ Doctor Good finally makes the following observation, which is quite significant in view of Professor Aslan's later findings:

"Another favorable side effect of the novocain therapy also must be mentioned, the improvement in the general well-being, and quite often a better mood of the patient. Patients who have been ailing and plagued by pains for years often seem quite depressed; they have dull eyes and are rather egocentric. They do not take any interest in people around them; their main occupation consists in an endless reciting of their ills and in tyrannizing other people. After a few weeks of continued novocain therapy the favorable change in the state of the chronically ill can readily be seen: Their glance is no longer directed inwardly, they look at others with friendlier eyes and now display a more lively interest in them."

Doctor Good did not follow up this observation, and it seems that he attributed the changed behavior of his patients not so much to a direct influence of procaine, but rather to a cessation of pain which. gave the sick and depressed people a psychological lift.

Doctor H. Warren Crow, Chief of the Charterhouse Clinic, designated GH3 procaine therapy as "the most valuable weapon in the treatment of the individual rheumatic patient." Edematic swellings in the joints are also reduced, and the treatment often leads to a lowering of the weight of the patient-perhaps due to a loss of water, of which too much has been concentrated in the peri-articular and subcutaneous tissues.

Since most arthritis sufferers are overweight, this loss of weight constitutes an additional gain.
At the Karlsruhe Therapy Congress in 1957, Prof. AsIan and Dr. Cornel David reported the results of a study of the effect of procaine therapy on degenerative joint diseases, as seen in 100 old men or prematurely aged patients. Ninety of these patients were hospitalized from 30 to 120 days, but remained under observation for another three to four years. Ten of the patients were under the Institute's care for over seven years. All patients received 5 cc injections of 2 per cent GH3 procaine, at a pH of 4.0, according to the regular schedule of treatment.
Of the 100 cases thus treated, 28 showed significant improvement, 60 some improvement, and only 12 were unchanged. '

"Cases judged to have 'significantly improved', according to Prof. AsIan, "included those where functional capacity had been restored, where both static and dynamic pain (pain in a state of rest or motion) had disappeared, where both active and passive motion had been regained, where physiological and biochemical tests showed a return to normal or in the direction of normal, and a few cases with remarkable restoration of normal skeletal structure. Cases adjudged to have 'improved' included patients with improved active and passive motion, with reduction in the duration and intensity of pain and return in the direction of normal of some physiological and biochemical criteria. Patients evidencing no significant effect of treatment were labelled 'unchanged'."

Professor Aslan's successes with procaine in arthritic patients are not as striking as those described by other physicians. Almost 40 years ago, on the basis of 40,000 procaine infiltrations in a variety of rheumatic complaints, Dr. E. Fenz reported 75 per cent cures, improvement in 15 per cent, and no change in only 10 per cent. Professor AsIan believes that the variable results she has achieved-and which are in line with the findings of Spiess more than 70 years ago and Leriche during the twenties-are due in part "to differences in central nervous reactivity, to differences in the reactivity in the organism, and various other complex internal factors, among which endocrine responses play a prominent role." In spite of this she advocates the broad application of procaine therapy in cases of osteoarthritis.

The New York physician Dr. David J. Graubard, used intravenous procaine therapy in rheumatic patients for many years. He and his co-workers administered intravenous procaine infusions plus Vitamin C either daily or weekly, and reported considerable improvement in most cases of rheumatoid, traumatic and osteoarthritis. In rheumatoid arthritis the pains and muscle spasms have been subsiding to a point where physical therapy could be begun. Best results were in osteoarthritis, where not only painlessness was achieved, but mobility of the joints also considerably improved. Only very advanced cases did not respond to this treatment.

Osteoporosis

Another malady commonly associated with old age, but occasionally occurring in younger people and even in children, is osteoporosis-the decalcification of the bones. It, too, has been combated successfully with procaine therapy. From 20 to 30 per cent of all old people suffer from this rather painful chronic disease, which also makes them extremely prone to fractures, particularly of the ribs and thigh. Sometimes younger women are affected by osteoporosis after surgical or X-ray castration, which indicates the connection between this illness and the functioning of the ovaries. The standard treatment today is a high calcium diet and the administration of androgens and estrogens (male and female sex hormones).

At the Institute I saw two small girls suffering from this disease. In one, the case was diagnosed at the age of six, when it was found that she was unable to write.
She underwent three years of unsuccessful treatment before coming to .the Institute. After four years of GH3 procaine injections, she was considered completely cured at the age of 13. Physically she was still underdeveloped, in relation to her age, but not to the degree that she had been in earlier years. Her menses had not yet started.
The other case had been operated upon and her hands placed in casts, which only worsened her condition and led to an osteoporosis of disuse. After several years of GH3 procaine injections, she was on her way to recovery.

According to pharmacological research conducted particularly by Prof. Eichholtz of Heidelberg certain diseases that were formerly treated with calcium, such as bronchial asthma, nettle rash (urticaria) and various skin edemas, respond just as well, if not better, to procaine injections. This would seem to indicate that GH3 procaine encourages the body's retention of calcium taken in through the diet.

Only recently it was found that other, hitherto untreatable diseases might yield to procaine. In 1971, Dr. Gaisford G. Harrison of the University of Cape Town Medical School suggested procaine in the treatment of a rare disease, malignant hyperpyrexia, which is a lethally high fever. It kills about 70 per cent of its victims, usually affecting people under 20 years of age. It can be triggered by a muscle relaxant and by halothane, a pain-killing gas, in people who are susceptible. Usually this disease leads to a temperature of 106 degrees Fahrenheit and rigidity of the muscles, often "merging into rigor mortis" (death), as the British Medical Journal has stated. Seemingly there is an abnormality in the calcium metabolism in the muscles leading to their contraction. Among the properties of procaine is to block some of the effects of calcium on the muscle physiology which may not only explain its efficacy in this rare and newly discovered disease but also its action on the rigidity of muscles in elderly patients, so often observed under GH3 procaine therapy.

Of even greater potential interest was the recent observation by Dr. Richard D. Baker of the Department of Microbiology at the University of Southern California in Los Angeles, that procaine hydrochloride may be useful in combatting the symptoms of sickle cell anemia from which many black people suffer. Small amounts of GH3 procaine appear to increase the flexibility of the membranes of deoxygenated red blood cells taken from sickle cell patients. Irreversible sickle cells, another researcher had found, are high in calcium and since procaine hydrochloride displaces calcium from the inner surfaces of erythrocyte (blood cells containing hemoglobin) membranes, it was only one further step to use procaine. Tests with human beings are now underway in Los Angeles.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3


BACK TO TOP

Chapter 20

Diseases of the skin, allergies and GH3

Perhaps one of the most striking sights in the old age home at the Institute is the repigmentation of hair that has occurred. This process is in different stages: in some people the roots are growing in according to their natural color, whereas the ends of the hair are still white; others, particularly blond people, once again possess a complete head of naturally colored hair. In others, whose hair was white when coming to the Institute, the hair has taken on a greyish tinge. Without exception, the GH3 procaine-treated patients have a healthy growth of hair, with any bald spots receding rapidly.

The trophicity of the skin is restored to almost normal: brown blotches disappear, wrinkles smooth out, and senile keratosis, ichthyosis and erythrodermia (the pathological reddening of the skin) are successfully combated. Other skin diseases also can be treated with procaine; among them scleroderma, leucoderma (the appearance of white patches on the skin, often due to syphilis), vitiligo (a congenital pigmentation deficiency) and psoriasis, as well as simple rashes and eczemas. The growth of nails as well as paradentosis (degenerative inflammation of the gums) are influenced through procaine therapy, facial hair had completely regrown. Since he still had, two large bald patches on his head, the treatment in his case was continued. In answer to my question, he said that he also felt better and stronger than before I he lost his hair, and had better power of concentration and a greater capacity for learning (all of which, of course, could be merely a psychological reaction).

Alopecia
The therapeutic value of procaine in this respect is indicated by the case of Maria Tabarcea, who came to the clinic early in 1955 with a total alopecia (baldness). After a little more than two years of GH3 procaine injections her hair had completely regrown, she was discharged as cured, and according to the doctors who have since observed her, her hair growth remains normal. "Before and after" photographs of Maria appear in the I photo section. In Bucharest, I also saw an 18-year-old boy who I some time ago lost not only the hair from his head but from his body and face, including the eyebrows. I After seven series of twelve injections, his body and head hair regrew. Vitiligo

The success of procaine injections in vitiligo, sometimes called piebald skin to characterize the discoloration of the skin on the face (and sometimes the hair), is indeed impressive: under the influence of procaine, the white patches disappear. While the occasional spontaneous disappearance of vitiligo has been reported, the curing of this badly disfiguring ailment with the help of procaine in almost every instance would seem to be indicative of the involvement of a Genuine healing process.

Scleroderma

One of the worst diseases known (fortunately quite rare) is scleroderma, also called sclerosis of the skin. While it is classified as a skin disease, it results ultimately in paralysis of certain muscles, ulceration of bones, and finally, complete invalidism and death, since so far no effective treatment has been found. At the Bucharest Institute 22 cases of scleroderma had been treated up to the time I visited there. I have seen one woman, now 37 years old, who has been under procaine treatment for three years, after having suffered from scleroderma for almost two decades. When she was brought to the Institute by her mother, the skin over her entire body had the color and consistency of wood, her face was almost expressionless, her nose was paper-thin, her finger bones (phalanxes) were ulcerated and about to falloff. Her knee joints were completely stiff, she was unable to open her mouth, was suffering from advanced paradentosis, had to endure excruciating pain and, according to the notation in her clinical record, was moribund. Since some of the internal organs were also affected, she had to be fed intravenously. For the most part she was completely apathetic. All possible forms of therapy had been used, including cortisone, but the disease continued to progress rapidly. She was brought to the Institute as a last resort.
Procaine treatments were begun immediately, at first according to the usual scheme, and then daily, but with an interval after every twelve injections.
Three years later, she was no longer in the clinic, but is an out-patient. Her body skin has regained full trophicity, except for that on her hands and forearms, which are still thin and emaciated, and which she can move only a little. Being a seamstress, however, she has recently begun to sew again with slow, narrow motions. She can talk for the first time in years; the paralysis of the mouth region is gone so that she is able to feed herself. She is without pain and walks, albeit with the help of a cane since her knee joints are still weak and will not support her for any length of time. She is still far from being a healthy person-but she had come a long way since 1956, and felt quite optimistic. Since she came to the Institute with such a long-standing case of scleroderma, the doctors do not completely share her confidence; nevertheless, it is most remarkable to hear about the transformation this woman has undergone. Several other cases of scleroderma now under treatment in the clinic are of relatively recent origin and are given a better prognosis. In view of the initial successes with this disease, new cases in Rumania are now immediately referred to Prof. Aslan, a procedure which gives them a much better change of recovery.

Psoriasis

The most dramatic evidence that procaine can be effective in curing psoriasis is the case of Tanasula Mircea, who had been suffering from psoriasis for 17 years, along with painful joint conditions which made him, at 42, a bedridden old man. He had been treated for five years with other drugs and with X-rays, to no avail. After 24 injections of GH3 procaine, he was able to walk again, and the psoriasis was clearing up. The change is shown in the photo section.
Again, the procaine treatment of psoriasis is no invention of Prof. Aslan. The first successful instances of such cures were reported in the literature about forty years ago. In the case of this dermatological condition, in which many parts of the body are covered with reddish, dry patches and greyish white scales, cure means a complete and permanent disappearance of the symptoms. Psoriasis has a tendency to improve spontaneously during the summer months, only to return with renewed vigor in the fall, for as long as symptomatic treatment is the only therapy used. Many cases of what seem to be true cures are recorded in the Institute's files.

Ichthyosis

Ichthyosis, the so-called fish skin disease, also has a good chance of being subdued by procaine injections, although it is generally considered incurable. This is an illness which manifests itself in earliest youth by keratinization of the skin, which usually lasts throughout life. The Institute reports that in the case of a 6th-year old girl suffering from hereditary muscular atony and ichthyosis (neither condition had responded either to other drugs or to physical methods of treatment) 60 injections of procaine produced not only a considerable alleviation of the muscular atony, but the reappearance of a trophic skin.

Bronchial asthma

Because bronchial asthma, like so many skin diseases, has been thought of primarily as an allergic reaction of the body, we will consider the effects of GH3 procaine therapy on this common affiiction in this same chapter. As we have noted, Prof. Aslan was using procaine GH3 to relieve asthma attacks when she first became interested in the therapeutic possibilities of this drug. Some Soviet research, however,. evidently predates the Bucharest work in this area.
Dr. N. K. Gorbadei reports that he began to use intra-arterial infusions of 0.5 per cent procaine solution with penicillin in the treatment of patients with bronchial asthma in 1943. This method has been tried in 32 patients (11 males and 21 females), 25 of whom had suffered from the complaint for over four years. In 17 patients attacks occurred over five times a day, and 11 had status asthmaticus (extremely severe attacks lasting from a few days to a week, sometimes fatal).
After four or five intra-arterial infusions of procaine GH3 and penicillin the general condition of the patients improved, the shortness of breath was relieved, the attacks of asthma were prevented, and the appetite and sleep improved in 30 of the 32 patients. In the remaining two patients, the attacks, although not completely abolished, became less frequent and less severe. Coughing diminished, and the normal rhythm of respiration was restored. Accompanying inflammatory changes in the respiratory organs were rapidly resolved. Again, as Prof. Aslan emphasizes, she had only made a 'rediscovery'.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 21

Cardiovascular diseases and GH3

As we know from an earlier chapter, the large-scale tests throughout Rumania directed towards the possible effects of procaine to prevent aging have shown that high as well as low blood pressure and too fast a pulse are frequently normalized. Equally, the longterm treatment of cardiac patients with procaine GH3 (usually for at least eighteen months) will often yield satisfactory results. Procaine has a vasodilatory effect, causing blood vessels to dilate, thus lowering the blood pressure. Arteriosclerotic conditions are improved, angina pectoris attacks diminish, heart thromboses show signs of faster healing. Intravenous injections have a favorable effect on cerebral spasms in older people; phlebitis, the recurrent inflammation of a vein, is easily overcome, and disturbances in peripheral circulation (after intra-arterial injections) are lessened.
The effects of procaine GH3 on these conditions have long been known and often described. In heart arrhythmies, treatment with procaine is standard procedure (there are in this country even oral procaine preparations available for this purpose). In other heart conditions procaine was prescribed as long ago as 1924.

The Soviet researcher N. K. Gorbadei, of the Leningrad Sanitary-Hygiene Medical Institute, examined over 70 of his peptic ulcer patients electrocardiographically before and after intra-arterial influsion of procaine H3. The general conclusions which Dr. Gorbadei derived from these examinations are:

Procaine, administered by intra-arterial infusion, has no toxic effect on the contraction of the heart muscle. The electrocardiographic studies of the patients seem to suggest that procaine infusions have a general action on the body as a whole, including the cardiovascular system, which is able to adjust temporary imbalances in the relative proportions of the excitation and inhibition of the nervous system.
The condition of the cardiovascular system before and after procaine infusions was studied by determining the tensio.n of the veins and arteries by a bloodless method-measuring the venous and arterial pressures, and recording simultaneously the changes in the volume of the limb and the blood pressure in ink with a device called the kymograph.

The initial. values of the arterial and venous pressures in the peptic ulcer patients were rather low, and the tension of the blood vessels was changeable, with a tendency to be raised.

After the first intra-arterial 'infusion of procaine a slight fall in the arterial and venous pressures was observed, presumably due to a fall in vascular tension as a result of procaine block.

However, after completion of the course of procaine GH3 infusions, most patients had higher arterial and venous pressures. The blood flow from the heart into the limb was increased, and the pulse rate slightly quickened.
The limb volume was increased because of the greater influx of blood. The tension of the blood vessels became more stable. In other words, the intra-arterial infusions of procaine had a normalizing effect on the vascular tone and on temporarily deranged reactions of the cardiovascular system. Subsequent infusions of procaine had much less effect than the earlier ones.
In peptic ulceration, changes in the cardiovascular system are present, in addition to the gastrointestinal disturbances, and can be recorded plethysmographically. These changes respond to intra-arterial infusions of procaine along with the improvement in the course of the ulcer itself. The conclusion is that this is a rational form of treatment, which acts on the body via the receptors of the blood vessels and the central nervous system.

Angina pectoris and GH3

At the same Institute, intra-arterial infusions of procaine were given to 20 patients (15 males and five female), aged from 20 to 71 years, who were suffering from angina pectoris-in most cases associated with early hypertension. (The patients were selected to exclude those with myocardial infarction.) All the patients were suffering frequent attacks of intense pain. The usual number of procaine infusions given was from four to ten.
After the treatment, 17 of the 20 patients were completely relieved of pain in the region of the heart, and the pain was less frequent in the other three. The frequency of the occurrence of palpitations and shortness of breath in the patients was also considerably reduced. The electrocardiographic findings showed improvement, the heart rate became normal, and extra systoles were abolished.
Similar results were reported in 1956 by F. F. Kilimatova of the Kazan State Institute for the Advanced Training of Physicians, who also used this method for relief of the pains of angina pectoris.

Varicose veins

Varicose veins is another of the diseases commonly associated with old age against which Prof. AsIan has found procaine GH3 injections to be a valuable medication. Other doctors had used procaine for the same purpose as long as forty-five years ago. The technique requires procaine injections around the affected vein or into the femoral artery. Here, too, procaine seems to have true curative power. Not only are the dull aches of the varicose veins relieved, but the condition itself, which is caused by a breakdown of the valves in the vein with subsequent unsightly enlargement, is favorably affected.
Prof. Aslan reports a number of cures of varicose veins without recurrence provided the causative circumstances (long periods of standing or sitting upright, or heavy lifting) were eliminated.
Why procaine GH3 should have such an effect on the veins is not clear. Some researchers believe there is some connection between the varicose veins that appear with increasing; age and the increasing failure of the endocrine glands to function properly. In view of the indications that procaine influences favorably less active endocrine glands, we may have an explanation why it is effective in many cases of varicose veins.
It is also interesting to note that in several patients with elephantiasis-like swelling of the lower extremities, caused by circulatory disturbances, improvement was noted after intramuscular procaine injections. (Sometimes elephantiasis is caused by the presence of parasitic worms in the lymphatic system, in which case procaine will be of no help.)

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 22

Gastrointestinal diseases and GH3

All patients treated with procaine have a markedly better appetite which, of course, may be an indirect result of their increased vitality. Procaine also seems to have a normalizing influence on the intestinal flora, but this has not yet been sufficiently investigated to allow any positive claims.

Ulcers

The most successful use of procaine in this area has been in the treatment of stomach and duodenal ulcers. Usually six intravenous injections suffice to stop the pain, and the ulcers themselves disappear after 24 injections, in most cases permanently. Only one of the Institute's ulcer patients had to be operated upon, and this proved to be for a calloused ulcer. Procaine therapy in ulcers was first recommended more than five decades ago, mainly by French and Belgian physicians. It is thought that the involuntary nervous system is affected by procaine, which in turn influences the etiology of ulcers.
Professor Aslan's chief assistant, Dr. Cornel David, reports that he himself had been suffering from gastric ulcers, which became completely quiescent after only five injections. In order to prevent recurrence, the Institute recommends that former ulcer patients undergo a prophylactic series of injections each spring and fall. Prof. AsIan's therapy is merely a rediscovery in this case as well. It was reported in the literature as far back as fifty years ago that up to two-thirds of all gastric ulcers were cured by use of procaine, as evidenced by X-ray data.
The Soviet researcher N. K. Gorbadei, reporting on procaine treatment of 171 patients with gastric ulcers, tells of rapid relief from the pain of the ulcer, normalization of the secretory and motor activity of the gastrointestinal tract, and disappearance of the dyspepsia. Objective evidence of the value of the treatment was found by X-ray, electrocardiographic, and plethysmographic findings.
A typical case history cited by Dr. Gorbadei tells of a female patient, aged 48 years, who was admitted to the hospital in 1954. The diagnosis was an acute stage of peptic ulceration, gastritis, and periduodenitis. She had been ill since 1951. X-ray examination on admission showed a duodenal ulcer crater measuring 0.3 X 0.3 cm, which was tender on being touched. After the fifth intra-arterial infusion of procaine, the patient was completely free from pains in the stomach, flatulence, heartburn, nausea and vomiting; her appetite improved, and the constipation, which had previously affiicted her for five to six days at a time, was relieved. During this time she gained over four pounds in weight.
One month later, further fluoroscopy and radiography of this patient showed no ulcer.
On the basis of more than 5000 intra-arterial infusions of procaine into the femoral arteries, Dr. Gorbadei and his co-workers consider that this technique is safe, simple, and more effective in the treatment of ulcers than the administration of procaine by any other method.
Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 23

Effects on the endocrine glands

Many of the changes observed by Prof. AsIan in the procaine-treated old people indicate that this substance acts upon the endocrine glands. Hair growth, as already mentioned, is stimulated; some testicular function, often almost dormant, is revived; small amounts of estrogen (the female sex hormone) are found circulating in old women again (the return of pigmentation to the labia minora is another sign of estrogenic stimulation); the adrenal glands become more active. The involution of female genitals usually is halted after several years' treatment, and in a few cases has even been reversed.
That procaine has a stimulating effect on the glands is also indicated by the fact that some doctors do not recommend use of procaine therapy in women prior to the menopause. This question has not been finally settled as yet, mainly because younger women have not been treated extensively, nor have any tests been con ducted on experimental animals. Several cases of amenorrhea (absence of menstruation) in women about 40 years old have yielded after one or two series of procaine injections, with regular menstrual periods appearing thereafter. Several cases of correction of sterility, which had persisted for many years in women with normal organs, are also on record. Procaine, without the addition of any hormones, was found to be of help.
Tests, first on mice, then on men, have shown that procaine inhibits the thyroid function, restoring this gland to normalcy in cases of over-activity. Much still has to be learned about the total effects of procaine on the endocrine glands. It will be interesting, indeed, if tests prove that procaine as well as aspirin, other analgesics, the cortical hormones, rutin (Vitamin P), calcium salt and antihistaminic substances, has the property of warding off the brittleness of capillary vessels.
In this respect, some wartime research conducted by Dr. Georges Ungar at Oxford University is of considerable interest. Dr. Ungar found many different procedures could protect experimental animals against traumatic shock. These procedures included the production of previous minor traumas, and the administration of ascorbic acid, procaine, cocaine, adrenaline, a whole cortical extract, an extract of the pituitary gland, and especially-the adrenocorticotrophic hormone (ACTH).
This researcher found also that the blood of healthy persons contains a substance which he believes is pro duced by the spleen, and which he called 'Splenin A', The blood of persons suffering from rheumatoid arthritis contains a quite different substance, which he called 'Splenin B'. Patients who have recovered from the disease again have 'Splenin A' in their blood.
Dr. Ungar found that under the influence of ACTH (the anti-stress hormone from the pituitary gland) the amount of 'Splenin A' in the blood of experimental animals increases, while 'Splenin B', if it is present, decreases. By ingenious experiments on guinea pigs and rats, he was also able to show that procaine, like 'Splenin A', reduces the bleeding time and increases the strength and resistance of the capillaries. Vernication of his research on a larger scale in 1952, reported by the British endocrinologist Dr. Raymond Green, indicated that procaine, like cortisone and ACTH, is capable of calling out the anti-stress hormones from the pituitary glands and the adrenal cortex, and also shows us how widespread was British interest in the potentialities of procaine in the treatment of old age diseases.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 24

Why procaine GH3 was “forgotten"

There is a well-known quip to squelch the braggart who is too enthusiastic about his own intelligence: "If you're so smart-why ain't you rich?"
In effect, we must ask the same question about procaine. If it is such an effective remedy in so many diseases, if it has been known to be effective in these diseases as long as seventy years ago, why isn't it being used by every doctor today? Why does the average practitioner still think of procaine only as a local anesthetic? To answer these questions, we need to look back at the medical headlines of a generation ago.
In a story entitled "Why Britain was wrong to drop it," the 'Daily Mail Doctor' wrote in that London paper as follows:

"When British doctors first began to show interest in the novocain treatment of asthma and rheumatism Oust after the second world war ended) shattering news came out of the Mayo clinic in America. Cortisone had been isolated as a drug, and was being used to make cripples walk.
"Dr. Hench, the man responsible, came to London in 1950 and was received like an Eastern potentate at the Royal Society of Medicine. The medical press hailed him. . . . So procaine was dropped as being of little interest now that the wonderous cortisone was available. . . .
"But ten years later the picture looks very different. The rosy promise of cortisone itself and of ACTH (the pituitary hormone which stimulates the flow of cortisone nom the adrenals) has not been fulfilled. It has turned out to be a twoedged weapon-curing some symptoms in the stress disorders, but making others very much worse. . . ."
The ‘Daily Mail Doctor' writes as if his personal experience with cortisone had been bitter-and bitter indeed was the disappointment of the world of medical science as it became apparent that the side effects and the long-delayed after-effects of cortisone in so many cases outweighed the benefits of this drug.
Hindsight is easy. The knowledge that has come with experience in use of cortisone in no way detracts from the accomplishment of its isolation. In its preparation and use, biochemists and medical researchers have learned much that will be of great value in the future of medicine and chemotherapy.
ACTH and cortisone are able to control such often excruciatingly painful states as rheumatic fever, arthritis, asthma, Addison's disease, certain allergies, etc. But if the treatment is discontinued, the symptoms of these diseases usually return. Moreover, the side effects often prove very disturbing: personality changes, gastric difficulties, and the syndrome of Cushing's disease (accumulation of fat in the face, the abdomen, and the buttocks) have been observed.
The medical profession is now fully alerted to the danger of overenthusiastic and undercautious use of cortisone and ACTH, and these drugs are used now only under the most careful supervision, so that patients will not have to suffer the untoward side effects.
Possibly the most unfortunate side effect of cortisone was the way in which excitement about its discovery cut off the growing medical interest in procaine as more than a local anesthetic.
Cortisone, as well as ACTH, has an antiphlogistic effect-which as long ago as 1906 Prof. Spiess claimed for procaine. The first two drugs do their work much more rapidly and dramatically, and indeed, are often indispensable. Procaine is less spectacular and requires a longer use before there are any signs of success, but it has virtually no side effects.
And just as medical science does not yet know how cortisone, ACTH, or even the time-proven aspirin work in the human body, so it has been very slow in solving the mystery of procaine's action.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 25

H3- a name for a riddle

The many changes that procaine brings about in the sick and aged body lead, of course, to the question of how this substance acts. Is procaine merely a catalyst? Does it combine with other substances to form some new compound? It has been suggested that procaine does not enter into the reaction at all, but merely frees certain enzymes. In spite of the efforts of many pharmacologists and biochemists, no single definitive answer has been evolved. Nor do we know why it should come closer to revitalizing old people than any other drug known, or why it should act as a psychic energizer in young people as well.
The current use of procaine, although limited, is ac tually a reversal of established laboratory techniques, wherein the substance under investigation must be thoroughly analyzed before it is put into use. However, strictly empirical therapy is not a new thing. Another important therapeutic agent, aspirin, has not been explored sufficiently to uncover its mechanism and mode of action. The parallel between procaine and aspirin is striking indeed. Both of these familiar drugs relieve inflammation and pain, and both reduce the crippling effects of arthritis. Aspirin, like procaine, improves the circulation of the blood.
Furthermore, neither of the two drugs is habit forming. Procaine parallels aspirin in another way that may be of considerable importance if procaine proves to be as effective against old age as Prof. Aslan claims-it is not an expensive substance to produce!
While, as we have mentioned, procaine has been of value in over 150 serious diseases and lesser ailments (not to speak of its importance in geriatric practice), aspirin has been used (mostly for symptomatic treatment) against some 200 illnesses. The mystery that surrounds the impressive histories of both these substances is deepened by the fact that medical science does not know why either procaine or aspirin act the way they do.
But while aspirin is an accepted drug-notwithstanding the risks its application entails, particularly gastric hemorrhages-procaine still has to fight for its recognition in this country although no undesirable side effect has become known (neither a possible allergic reaction nor its incompatibility with sulfa drugs can be classified as such).
Procaine, we may briefly repeat, is hydrolyzed in the body into two substances, para-aminobenzoip acid and diethylamino-ethanol. Both have been extensively studied but in themselves do not have all the effects procaine exerts. Para-aminobenzoic acid (PABA) was found to be necessary for normal pigmentation of hair in the rodent, maintenance of a normal fur coat in the rat, and for the multiplication of certain strains of bacteria. It is present in yeast and liver extract, and is considered a member of the Vitamin B complex. As such it has been given the name HI. But so far it has been impossible to determine PABA's exact role in the human body; we do not know whether it is necessary either for the body's nourishment or its functioning.
Diethylamino-ethanol (DAE), the other component of procaine, is believed to be more responsible for the properties of the parent drug than PABA, but in itself does not account for the beneficial effects of procaine.
DAE, according to pharmacological textbooks, induces local anesthesia, exerts a quinidine-like action on the heart, a spasmolytic effect on smooth muscle, and also posseses analgesic and antiallergic action. In particular it has proven its therapeutic value in the treatment of heart arrhythmies, where it is thought to be even more effective than procaine, although it must be administered intravenously in considerably higher doses. This is of no concern, however, since DAE is even less toxic than the almost nontoxic procaine.
Neither PABA nor DAE has a trophic effect on the skin, nor do they stimulate the general metabolism of the body (leading to an increase in weight) as strongly as does procaine. For that reason it must be assumed that the procaine molecule as a whole must have a very specific effect. Whether this is vitamin-like, as Prof. AsIan believes, whether it has something to do with the production of acetylcholine in the cell structure, as other researchers surmise, or whether a direct influence on the central nervous system is involved, has not yet been proved. Perhaps it is a combination of two or more of these actions.
Rather quietly, a preparation made in Germany, was introduced in health food stores late in 1977. It's name "Omega- H3." It did not as could be inferred from the name, contain procaine, but only paraminobenzoic acid which, as we have seen, is a hydrolysis product of procaine. The distributors of Omega- H3 speak of PABA as an "improved form of procaine, which has world wide scientific recognition as a health promoting factor. . . . This led to the use of PABA in Omega-H 3, which is a vast improvement and superior in every respect to the original procaine."
We have quoted from this prospectus only to criticize the unscientific approach to consider part of a substance a "vast improvement" on the whole substance which in turn is better than the sum of its parts. Omega-H 3 may be a valuable adjunct to nutrition for it contains many vitamins and pollen extract-only an equivalent of any of the procaine preparations it is not!
G. N. Udintsev and V. B. Blank of the Leningrad Sanitary-Hygiene Medical Institute reported in 1957 on their study of the morphological changes in the blood of 150 peptic ulcer patients, before and after procaine infusions. Their results revealed that there is no toxic action of procaine on the bone marrow, and they believe that the changes in the blood produced by procaine are brought about by reflex redistribution of the blood in the body and by reflex action on the bone marrow and hemopoietic system generally.
Soviet researchers have been actively studying and reporting on the effect of procaine on the body, and the mechanism of its action for as long as 40 years. The recent book by N. K. Gorbadei discusses applications of procaine in the treatment of peptic ulcers, and reviews the theories of the mechanism of action of procaine. After citing the theories put forth by various Soviet biochemists and physiologists as long ago as 1934, Gorbadei continues:

"On the basis of the foregoing we may conclude that no unanimity yet exists with regard to the interpretation of the mechanism of action of procaine. In the opinion of A. V. Vishnevskii, A.D. Speranskii, and N. I. Leporskii, by whatever means it is administered, in addition to its local action procaine also has a general action on the body. This general action of the drug is due to normalization of the processes of inhibition and excitation in the central nervous system.
"Our experimental and clinical findings give grounds for the assertion that when given by intra-arterial infusion, besides its action on the vascular receptor apparatus, procaine has a general action on the body as a whole, through the central nervous system. The intra-arterial infusion of procaine thus has an indirect action on the body via the neurovascular receptor apparatus and the central nervous system. The action of procaine undoubtedly depends on the initial functional state of the nervous system, and on the mode of administration. The diversity of the functional changes resulting from procaine administration, the speed of the reactions to it, and the manifestation of the effect far from the site of injection all underline the role of the general, evidently reflex, action of procaine rather than its local action. This is in agreement with the findings of Andreeva, Komarov, and Timeskov (1957), who consider that the therapeutic effect of visceral anesthesia is mainly dependent on the general neurotropic action of procaine on the body.
"Most authors thus consider that procaine acts through the nervous system. At this point, however, their views diverge. . .
"From the data in the literature and our clinical observations, there are grounds for believing that an essential role in the mechanism of the intra-arterial infusions of procaine is played by nervous reflex influences arising from the receptor apparatus of the blood vessels, as well as by humoral factors, after the entry of the procaine into the blood stream."

As was to be expected, Prof. Alsan herself, wanting to know more about the mechanism of procaine, has done extensive research at her Institute, particularly in plants and animals. This is not the place to describe the highly technical experiments which, while interesting in themselves, have not led to more than a hypothesis as to why procaine brings about the mentioned effects in human beings. Her conclusion: that procaine has a distinct vitamin like effect, but that it may also act as a biocatalyst (speeding up or slowing down certain chemical processes). It was in order to distinguish it from PABA that she proposed to call procaine H3, which is the official name of the buffered procaine she is using in the treatment of her patients.
That the vitamin like effect of procaine is the answer to the riddle may be doubted in view of the fact that, as a rule, procaine is much more successful in the treatment of old age than even extended vitamin therapy. Also the signs of "rejuvenation" appear much faster than in people largely treated with vitamins. As explanation, if one is possible, should also be forthcoming as to why the few milligrams of PABA set free when the injected procaine hydrolyzes should be able to maintain in a patient a more youthful appearance for months, as sometimes happens after only one or a few injections of procaine.
As an aside, it is interesting to note that the coca leaves commonly chewed by Peruvians and Bolivians living on high mountains have some of the effects now ascribed to procaine. Cocaine has been derived from the coca leaves and, as we have learned, procaine was synthesized as a substitute for the toxic cocaine, which is habit forming. Strangely enough, the coca leaves do not have this effect; when coca chewers move to the cities, they usually stop using it. While digesting coca leaves, they drink and smoke little (as a matter of fact, infusions of coca capsules are being used for breaking the drinking and smoking habits without creating the danger of addiction). According to medical investigations, coca acts as a heart tonic, stimulates the contractions of the heart, thereby enriching the body with oxygen, and increases the excretion of nitrogen, chlorides, sulfates and phosphates in the urine, which may be the main reasons for the sense of well-being engendered when it is chewed. Its anesthetic effects on the palate and the mouth alleviate feelings of hunger and thirst, enabling coca chewers to walk up to fIfty miles daily without fatigue and without any intake of food. Tests made on Indians during and immediately after their coca chewing showed an increase in the metabolic rate. This rate remains high with chronic coca users, clearly showing a stimulation of the metabolism as a whole. No observations have been made as to whether coca may also have some eutrophic effects.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 26

DMAE-a related mystery

While with the exception of the MAG inhibiting theory of procaine little original pharmacological work has been done in this country, some very interesting information has come to light concerning the action of dimethylamino-ethanol (DMAE), a slightly changed form of diethylamino-ethanol (DAE). Prof. Carl Pfeiffer, professor of pharmacology at Emory University in Atlanta, Ga., and his co-workers have reported their findings in Science Guly, 1957) and the Journal of Pharmacology and Experimental Therapeutics (1958). Since their research may contain a clue which will help researchers answer the riddle of how procaine works, we summarize it here.
Daily oral doses of 10 to 20 mg DMAE within seven to ten days produce a mild and pleasant degree of central nervous stimulation, which is characterized by less fatigue and sounder sleep. Also, fewer hours of sleep are needed. Larger doses may result in increased muscle tone but may also produce insomnia. The stimulation of the central nervous system is not accompanied by a rise in blood pressure, a rise in body temperature, or a change in the plasma level of protein-bound iodine.
The similarity between DMAE and the DAE component of procaine and the similarity of the effects produced by these two compounds in the human body would indicate that when medical science learns how one works, it will also understand the mechanism of action of the other.
In Prof. Pfeiffer's second paper he discussed a double-blind study, comparing DMAE therapy to a placebo. A questionnaire was used to supplement weekly measurements of heart rate, blood pressure, muscle strength, hand steadiness, vital capacity and body weight. This therapy continued for three months, and during the last six weeks all students were being treated with D MAE. In Prof. Pfeiffer's own words:

"Significant subjective changes found in the DMAE-treated group were increased muscle tone, increased mental concentration, changes in sleep habits. In most instances the sleep habit was less sleep required. Others reported sounder sleep with earlier, clear-minded awakening. A mood change to greater affability or mild euphoria was coupled with a more outgoing or outspoken personality. No significant changes occurred in heart rate, blood pressure, muscle strength, handsteadiness, vital capacity and body weight. . . . Twenty-five out of the 35 students noted mental stimulation, which increased daily in the fIrst week of medication and was greater than that produced by amphetamine [a so-called "pep" pill]. Five students discerned no effect at the dosage used. Unlike that produced by amphetamine, the DMAE stimulation lasted 24 to 48 hours after discontinuation of the dosage, and was not accompanied by a rebound period of depression. An overdosage produced insomnia, muscle tenseness and spontaneous isolated muscle twitches."

Other researchers have since reported similar effects with a DMAE drug called Deano!. Two members of the University of Washington School of Medicine, in Seattle, have stated that in a group of 100 patients suffering from various psychiatric disorders, especially exhaustion and depression, increased energy and lessened depression were noted in most cases after the initiation of the therapy with Deano!. Improvement usually occurs within a few days and no side effects are observed, except for occasional overstimulation, which is controlled by a reduction in dosage.
Four years ago, Richard Hochschild reported in Experimental Gerontology that DMAE which is synthesized in very small amounts by human beings and which is found in all living organisms, may retard the aging process. In his experiments with senile mice, Hochschild found that when treatment was begun past the mean expected life span of the animals, the treated group had a mean survival time of 85.1 days as against 56.9 days for the controls, an increase of 49.5 per cent. In another experiment, mean survival time of white mice was 12.39 months after the onset for the DMAE-treated group and only 9.73 months for the controls, a life extension of 27.3 per cent. In view of its very low toxicity Hochschild recommends further tests with D MAE in relation to its role in the human aging process. These tests could also throw additional light on the efficacy of procaine.

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 27

Can procaine postpone old age?

The most dramatic aspect of the procaine therapy is the possibiltity of its use as a prophylactic measure, to ward off the symptoms of old age, or at least to postpone them. On the surface it would seem that this could be the case, but the complete lack of old age criteria will make it difficult to prove or disprove the prophylactic effectiveness of procaine in human beings.
We have no way of determining the physiologically "normal" state of a 65-year-old man: we do not know how much sickness to consider "normal" in a man of that age. At best we may arrive at certain statistical data by examining a large number of 65-year-old people and striking a chronological average, but we are still in the dark as to the true picture each man or woman should present biologically at a certain age.
With this in mind, we can readily see how difficult it will be to gauge any prophylactic effect of procaine in an objective manner. Suppose we start a group of 45year-old people on a modified procaine therapy, as has been done in Bucharest and elsewhere, and treat another group of the same age with another substance or with a placebo. Can we really set up standards of what to expect in these people, provided even that their physiological conditions at the beginning of this experiment are approximately the same? The subjective story might be different-an absence of vague complaints, a less frequent occurrence of nervous and joint diseases in the procaine-treated group, or, as the tests started in Bucharest in 1972, the lower incidence of cardiovascular diseases, would make the value of such prophylactic treatment clear.
The prophylactic use of procaine is not completely in the realm of speculation, as may be inferred from the fact that premature aging has been successfully reversed. We have heard of the particularly striking case of the 42-year-old man; similar but not quite so dramatic cases are to be seen almost daily at the Institute of Geriatrics. One Bucharest patient was observed in whom further aging seemed to have been arrested for a period of seven years.
We have mentioned that the Geriatrics Institute has under its care a surprisingly large number of children with either unusual diseases (osteoporosis, ichthyosis, etc.) or with more common ailments, such as asthma and rheumatism, which respond readily to procaine. Cases of the latter type are explained by Prof. AsIan as instances of precocious aging of the organism. She feels that neither bronchial asthma nor rheumatism will normally occur in children, and that we are dealing in such cases with relatively rare symptoms of old age in the young. (In girls, procaine therapy must be administered very judiciously, since procaine stimulates the ovaries. The potential benefits must outweigh the possible danger of hormonal overstimulation.)
While procaine has proved itself in the simpler cases, it is recommended that the treated children continue periodical procaine therapy in order to prevent any recurrence of these untimely signs of old age. The state of health in these children in the later years will be of great interest to medical science.
It should also be interesting to observe whether procaine can be of any value in a very rare condition called "progeria," a form of senility which is apparent by the end of the first year of life. Very few cases of progeria have been described, and all of them have led to death before the 26th year of the affected individuals. These children show atrophic skin, baldness, calcification of the vessels, osteoarthritis, osteoporosis, sexual retardation, tremors of the limbs-in other words, all the signs of senescence with the exception of cataracts. Death is usually due to coronary insufficiency. The cause of progeria is still unknown, but since procaine favorably affects most of its symptoms, it would seem logical to institute this therapy in cases of such accelerated aging.
Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital G-H3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 28

Why all the excitement?

We have seen that there has been no miracle drug discovered at Bucharest, that "H3" is merely a new name for something not fully understood about a very old and familiar drug-procaine hydrochloride. We have seen further that other doctors used procaine before (sometimes long before) Prof. AsIan, to treat exactly the same stress diseases. We have learned that there is still no sure answer to the riddle of how (or to what extent) procaine works in the human body, and we see that thus far there is no positive indication that procaine can postpone the normal onset of old age.

Then why all the excitement?
Because while others have applied procaine in the relief of one or another stress diseases (and stopped if the treatment was not promptly successful or as soon as some symptomatic relief was obtained), Prof. Aslan saw old age as a complex of these same stress diseases, and procaine as a potential weapon in the battle against old age itself.
Her reports that procaine is effective not merely as a therapy against one or another disease, but against the debility, the helplessness, the childishness and the senility of old age, are tremendously exciting to the entire world, for old age strikes every man and woman who survives maturity.
In the United States alone, there are today more than fifteen million persons above the age of sixty-five. By the end of this century, this group may number close to thirty million. These figures point up the scope of a great national problem, for while aging may still be considered a crisis for the individual, it is today the concern of the community as a whole.
So far, our main emphasis has been on improvement of the care for the elderly. Up to now, medical science has failed to come to grips with the task of treating old age. Nobody is more intimately aware of this situation than are those physicians who deal mostly with old people.
Says Dr. Edward J. Stieglitz of Washington, D.C.: "Health is a lot more than the absence of disease. Pediatrics has been making healthy children healthier. Geriatrics could do the same. The trouble is that doctors think entirely in terms of disease, and are ignoring their opportunities for making aging people healthier."
This is the opportunity which was not ignored by Prof. Aslan-the opportunity to search for a therapy which would make aging people healthier.
It has been remarked that with old age the good characteristics of man diminish, while the bad ones increase. It is this very manifestation which tends to make old people valueless, superfluous, expendable. By the same token, it makes them a burden to the younger generation, individually as well as collectively.
"Most of us are likely to feel almost instinctively that youth is everything and that old age is a disaster", Dr. Michael M. Dacso, once director of physical medicine and rehabilitation at N ew York's Goldwater Memorial Hospital, stated. "We pity old people. Often we avoid them. Sometimes we laugh at them." To our current way of thinking, as psychiatrist Dr. Jack Weinberg of Chicago's Michael Reese Hospital has so aptly put it, the aged are "simply people without a future." Or, as Prof. Eisfelder said so succinctly, "the question is whether we will merely create a larger pool of superfluous human beings out of our older citizens or integrate everyone into the total society."
Obviously, this can only be done when more research money for the health problems of our aging population becomes available. "The total budget for extramural aging research in the United States in fiscal 1972 was two and a half million dollars," says Eisfelder. "That was not enough to continue the research already funded, and it meant that out of every hundred grants on research in aging, only one was being supported with federal money."
While some improvement in this field has taken place during the last five years, the small amounts spent on aging research must be seen in relation to the hundreds of millions expended year after year for cancer research-yet many more people" age" than develop cancer. The aged, in spite of the strides made in recent years, have remained medicine's stepchildren.
The attitude of defeatism which has been characteristic of so much of the world's effort on behalf of the elderly may be changed through the application of the procaine therapy if it will prove as effective as Ana Aslan and the other researchers believe on the basis of their findings we have detailed on these pages. For this is the first proposal for a treatment for old age which could be used on a broad scale because it is simple to administer, inexpensive, and not habitforming.
Why then, considering the many positive reports by American scientists, the foot-dragging by the FDA? Why the opposition of so much of the medical establishment? Is it that what is accessible to the elderly in some eighty countries df the world, is not good enough for America's aging? We are awaiting the answers for we feel that with the procaine therapy available, the battle against old age has been joined!

Vitacel GH9 - Vitacel GH8 - Vitacel GH7 Plus - Vitacel GH7 - Aslavital GH3 - Zell H3 - Gerovital GH3

BACK TO TOP

Chapter 29

What Does H3 Mean to You?

After reading the foregoing 28 chapters you feel that procaine hydrochloride in one of its many versions may be able to do you some good, a word of warning is in order: The obviously harmless preparation is not yet generally available in the United States. During the last twenty years millions of H3 'injections have been given and tens or hundreds of millions of H 3 pills have been taken-and we are still waiting to hear about any major or even minor side effect. We were unable to find any such report in the many research and clinical papers written about H 3. A few people may have discontinued the medication because they developed a headache or felt nauseated-symptoms that can occur with any drug and which have been observed even with placebos.
Thus we can lay to rest any doubts that may still persist as to procaine's safety. It is certainly safer to take than aspirin of which a number of untoward reactions have been discussed in the medical literature, foremost the possibility of intestinal hemorrhages if taken in too large doses. But what about the efficacy, you may ask? There are scores of papers written by researchers and clinicians in many parts of the world attesting to the various beneficial influences of H 3 on the human body. Were they to be put together, they would make a book at least twice as thick as the one you are presently reading. To anyone interested, the author will be happy to send an extensive bibliography containing all reports which have become known, some from Rumania, where the initial work was done and the basic papers written; from Central Europe, particularly from Western Germany, which has taken to procaine perhaps more enthusiastically than any other country, and from this country where many promising papers were pouring forth until last year the clinical trials were completely suspended.
The future road of H3 in this country may still be rocky and it is entirely possible that some of the H3 producers will use the Laetrile model for their preparation too-getting it approved for distribution within individual states where the FDA has no jurisdiction.
Whether this may lead to the more general availability of such controversial drugs-remains to be seen. It is an uncharted road although Melvin Kratter, the Nevada industrialist, who been able to gain admission of procaine against depression in that state, recently declared that he will be ready for production in the summer of 1978. As of this writing this may turn out to be the most promising way to gradually obtain general clearance of H3 preparations in the United States-provided enough interest is generated to make other states' legislatures follow the Nevada example. The lengthy administrative procedures established by the FDA since 1962, when the new Food and Drug Law took effect, obviously retard the introduction of ne~ drugs. While this has helped in some instances to keep dangerous drugs off the American market notably Contergan, it has-in the case of H3 -prevented a medication available over the counter in some eighty countries, from helping us in the fight against the most widespread disease-old age. In recent months Joseph Califano, Secretary of the Department of Health, Education and Welfare, as well as Dr. Donald Kennedy, head of the FDA, have publicly deplored the effect of current drug regulation and have called for changes. These might come when either the whole Department or the FDA will be overhauled which seems to be one aim of our government.
Thus whether Americans will be able to get H 3, may depend on the settlement of the larger question of government reorganization. In the last analysis, it is a question of whether there is a need of overprotecting the people of this country by a Federal bureaucracy from a drug which has proven its value all over the world. Here is a case where we still practice a provincialism which we have discarded in most other fields, knowing full well that the interdependence of nations and people does no longer allow us such luxury. Health, old age, the prevention of disease are matters of international scope; they become our concern wherever we live, and therefore it behooves us to look at them within an international framework. The saga of H3 in this country is a story of bureaucratic distrust of an internationally successful drug. It is a distrust which hurts all of us.

BACK TO TOP

Related pages: GH3 Will It Keep You Young Longer? / Home – Diseases Makeovers / GH3 F. A. Q.

This site is a member of WebRing.
To browse visit Here.

BACK TO TOP


ONLINE PRODUCT CATALOG

1- 888- 804-HEAL(4325)
Phone Orders PST

Full feature secure shopping
Full feature Cart
Click on Logo

Vitacel Testimonials

vitacel gh3 natural antiaging health supplement Original - Formula

Vitacel GH3
Dr. Koch GH3
Read More...





vitacel 7 gh7 natural antiaging health supplement 100 mg - Formula

Vitacel 7 GH7
Dr. Koch patented Improved GH3
Read More...



vitacel 9 antiaging antioxidant supplement BEST VALUE!

Vitacel 9 GH9
Dr. Koch patented formula
Ingredients include: Vitacel 7 GH7 Base, CoQ10, L-carnitine, Lycopene
Read More...



Vitacel 8 natural antiaging health supplement BEST VALUE!

Vitacel 8
Dr. Koch patented formula
Ingredients include: GH7 Base, Grape seed, Ginkgo Biloba, Milk Thistle, Artichoke Extracts
Read More...


Vitacel 7 natural antiaging health supplement Double Dose GH7
200 mg Formula


Vitacel 7 PLUS
Dr. Koch Antiaging supplement Read More...



HEALTH PRODUCTS FOR PEOPLE

VITACEL - With PBN’s (Procaine Based Nutriments in GH9 to G-H3)

Vitacel 9 - Vitacel 8 - Vitacel 7 Plus Vitacel 7 - Vitacel 7 Liquid - Vitacel 6 Vitacel 5 - Vitacel 4 - Vitacel 3sp Vitacel 3

VITALIZE SKIN CARE CREAMS AND LOTION -With PBN’s (Procaine Based Nutriments)

Vitalize Aloe (Lotion) - Vitalize Therapeutic Face, Hand and Body cream – 4oz., 2oz, ½ oz (Trial size)

VITAMINS / HERBS – Dietary Supplements

Cal-Mag - C-dophilus Plus - CEM Herb - Flavanol - Gingko - Milk Thistle - MSN - Vita Joint - Vita-Mins



HEALTH PRODUCTS FOR PETS

With PBN’s (Procaine Based Nutriments)

Vital Pet - Vital Pet Plus - Vital Pet Mega



INSTRUCTIONS FOR USE


UNDERSTANDING THE HEALING PROCESS

Dr. Robert Koch, DSc.

“I find that the more severe the individual’s condition (more toxicity in the body), the stronger will be the healing reaction...the healing reaction is caused by flushing toxins out of the cells...
(Read More…)
  • Why old symptoms
    come back
  • Drugs that block pain may also stop healing
  • Some natural ways to ease the healing reaction


SPORTS / FITNESS / HEALTH

Vitacel GH-7 for Longevity, Strength and Recovery

“Since then, a new product has emerged called Vitacel 7 GH-7, which is superior to the other GH-3 formulas and contains a variety of nutrients including procaine HCl. The two primary uses of Vitacel 7 are to slow the aging process, increase strength, and speed the recovery of athletes.” (Read More…)



WHY DID 35,000 GH–3 USERS SWITCH TO VITACEL GH-9 GH-8 AND GH-7 PRODUCTS?

“Vitacel GH-9, GH-8 and GH-7 are 6 times (600%) more potent than the original GH-3 formula because of the 100% complexing of the procaine.” (Read More…)



THE ORIGINAL GH-3 - Versus - THE VITACEL 7 (GH-7)

Vitacel 9 and 8 (GH-7) is the most cutting edge, improved procaine complexed formula by up to 600% over the original GH-3 formula. The Vitacel procaine works much longer in the blood stream to cleanse, feed and repair damaged cells. Dr. Koch has been granted over $100,000 in US and Foreign Patents for the advanced Vitacel 7 formulas… (Read More…)



EVOLUTION OF PROCAINE GH-3 – SINCE 1905

Dr. Albert Einhorn, Dr. Ana Aslan and Dr. Robert Koch

Procaine Hydrochloride was first synthesized in 1905 by a German chemist Albert Einhorn. He was looking for a compound that would act as an anesthetic, would be non-toxic, free of side effects, and would not be addictive. (Read More…)



THE BODY CRIES FOR WATER

Nutrition, Fitness and Health “The truth is that dehydration can cause diseases like asthma, hypertension, peptic ulcers, allergies and arthritis. Everyone knows that water is good for the body but not how essential water is to well-being. They don’t understand what happens to the body if it doesn't receive its daily water requirements.” (Read More…)



CARBS / PROTEIN / FAT GRAM COUNTER:

Carbohydrate / Fat Gram Counter Carbohydrate / Fat Gram Counter Fast Food Calorie / Fat Gram Counter Burn 500 Calories a Day

Related Anti Aging research
discoveries LINKS...

Actyl L Carnitine - Pet Liquid Vitamin - Natural Vitamin Supplements - All Natural Vitamin Supplements - All Natural Skin Care Products - Artichoke Extract - Calcium Magnesium Vitamin D - Celadrin Softgels - Good Cholesterol Levels - Blood Circulation - CoQ10 Coenzyme Q10 - Fibromyalgia Syndrome Chronic Fatigue - Foods that Fight and Prevent Cancer - Ginkgo Biloba Benefits Benefits - The Truth About GH3 Dietary Supplements - The Truth About GH3 Dietary Supplements - Ginseng Side Effects - Ginseng Benefits - Grape Seed Extract Benefits - Green Tea Extract Benefits Side Effects - GH3 Vitamin Supplement Review - Ways to Prevent Heart Disease - Ginseng Benefits - HGH Human Growth Hormone Side Effects - Canine Dog Hip Dysplasia - Best Hoodia Gordonii - Arthritis Knee Pain - How to Lower High Cholesterol - Common Sports Injuries - Niacin Side Effects Cholesterol Benefits - Parkinsons Symptoms - Parkinsons Disease Therapy Treatment - Pet Meds Online - Pet Health Symptoms Questions - Pet Vitamins - Anti aging Supplement Discoveries - Alternative Arthritis Remedies - Ginseng Benefits - Stroke Symptoms Sign Of… - Diabetes Signs and Symptoms - Natural Healing - Ginseng Benefits - Drinking Water Benefits - Super Health Anti Aging Supplements - All Natural Pet Medicines - Natural Pet Vitamins - Pet Health Problems - Pet Health Questions - Vitamin Supplement Benefits - Life Extension Anti Aging Research

89% POSITIVE HEALTH BENEFITS GH3 PROCAINE Antiaging research

Healthy aging Clinical research data from the Parhon Institute in Romania...Click here to Read article...

H3 - In The Battle Against Old Age - by Henry Marx

TRUTH ABOUT GH3 dietary supplements... (Click here to read Book...)

VITACEL GH3-7-8-9 - THE WORLD’S BEST KEPT SECRET arthritis benefits research...

Take heart! There is no need to suffer from the pains etc of arthritis. The Alternative ALL Natural GH3-7-8-9 health solution to arthritis has been around since 1949… Then came the development of authentic VITACEL GH3-7-8-9 antiaging vitamin supplements. These Nutritional Supplements Alt Natural Medicine products provide faster and greater relief from arthritis than did the GH3). (Click here to Read article...)

DR. KOCH PATENTED New and Improved SUPER GH3-7 PLUS = Healthy Aging...

Dr. Robert Koch, DSc. organic biochemist and inventor of many chemical processes became interested in the GH3 anti aging vitamin health benefits in 1981.

Dr. Koch’s sister, who suffered from asthma found out about GH3 and obtained some through a friend. The nutritional supplement GH3 was very effective in controlling her asthma, to such a degree that Dr. Koch became interested in why this anesthetic procaine HCl could be effective against asthma. He did a literature search in the Medical Library and to his amazement there were over 600 articles about the Anti-aging benefits of GH3 and of various other cellular benefits of procaine HCl. Since that time Dr. Koch has spent his time researching the Anti-aging effects of this Alternative Natural Medicine on degenerative diseases.

Dr. Koch had tested GH3 made by a company in the U.S. and found that the tablets were nothing more than a mixture of the powders that make up GH3. They didn’t contain the authentic GH3 factor that was the effective agent in the Aslan injectables. He tested some of the Romanian tablets and found that they didn’t contain the authentic GH3 factor that was contained in the injectables. They were no more than a mixture of the powders in tablet form.
(Click here to Read article...)

THE TRUTH ABOUT WHAT DOCTORS HAVE TO SAY ABOUT GH3

“Basically, there is only one disease – Malfunction of the cells. Improve the functions of the cells and you improve every facet of your body. VITACEL GH3-7-8-9 works on the CAUSE of aging not the SYMPTOMS of aging…SYMPTOMS disappear as the CAUSE is remedied.” Dr. Koch

"GH3 is a state-of-the art anti-aging aging with grace formula. Anyone who wants to prevent or alleviate age-related diseases should be taking GH3 anti aging DIETARY SUPPLEMENTS every day". Dr. Hans Kluger

"GH3 quickly improves the function of every organ in the body, grey hair diminishes and loose, wrinkled skin becomes firm and smooth as if you had a face-lift!" Dr. Ronald Klatz

“I have tested all of the GH3 anti aging dietary supplements sold around the world, at least those that I know of, and not a single one; including the Romanian tablets contain the complex or GH3 factor. Even though they contain all of the natural components of GH3 they are but a mixture of the powders, in tablet form.” Dr. Koch

“Dr. Nathan Kline, former associate professor at Columbia University College of Physicians and Surgeons made a study on the safety of GH3. He gave both humans and rats up to 60 times the optimum dose of GH3. Neither the rats nor the humans experienced any side effects." (Click here to Read article...)

HOW GH3-7-8-9 WORKS! (Click here to Read article...)

MORE PUBLISHED MATERIAL ON GH3 (Read More…)

HEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETSHEALTH MAKEOVER FOR PETS